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Strategies for prevention, circumvention, and reversal of drug
resistance in tumor cells
Abstract
Both the intrinsic and the acquired anticancer drug resistance presents until today a major drawback in
the management of cancer. The handling with drug resistance is aggravated by the facts that drug
resistance is a multifactorial and multifaceted phenomenon. The development of tumor-targeted
pharmacological and genetic strategies to overcome intrinsic resistance and to prevent the resistance
acquisition is thus still a pressing need. We put forward the two main objectives: 1) The reversal of the
pre-existing drug resistance in p53-deficient cells by either the concomitant abrogation of DNA repair
functions or by the concomitant blocking of cytoprotective signaling pathways. 2) The identification of
members of the novel class of histone deacetylase (HDAC) inhibitors with anticancer activity that have
(or do not have) the potential to cause resistance acquisition in tumor cells. 	Mutations in the p53 gene
and dysregulation of p53-dependent cellular processes are often associated with cancer and resistance to
radio- and chemotherapy. Many Advances have been taken to reconstitute the (wildtype) p53 tumor
suppressor pathway in cancer cells. We showed that genetic abrogation of the expression of the DNA
mismatch repair (MMR) gene Pms2 in cells depleted for the p53 tumor suppressor function
hypersensitized these cells to the cytotoxic effect of some anticancer agents through an increase in the
rate of apoptosis. Expanding on this, we also showed that genetic depletion of either ATM, BRCA1, or
DNA-PK resulted in an increase in the chemosensitivity of p53-deficient cells against a variety of
anticancer agents. These studies indicate that tumor-targeted functional inhibition of either one or the
other of these DNA repair genes may reverse resistance in p53-mutated tumors and therefore provide a
strategy for increasing chemotherapy efficacy for these tumors. Analogous as well as opposing results
were reported for loss of the MMR protein MLH1 in p53-deficient cells with Cisplatin. However,
neither Radicicol (HSP90 inhibitor) nor LY294002 and LY294005 (Akt inhibitors) were found to
reverse Cisplatin resistance specifically in MMR-deficient tumor cells. These Akt inhibitors even further
decreased the sensitivity against Cisplatin, suggesting - in addition to its acknowledged cytoprotective
function - a cytodestructive function of Akt. 	On the other hand, we showed the potential of the HDAC
inhibitor SAHA to induce stable and MDR-independent resistance in HCT116 colon tumor cells. As
these results differ from those reported with FK-228, we propose a novel mechanism of resistance
acquisition by the SAHA, the nature of which is still obscure. This is under investigation, as is novel and
intriguing molecular approach to reverse drug resistance: the liposomal delivery of (exogenous)
cytochrome c to tumor cells. 
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 1. Summary 
 
Both the intrinsic and the acquired anticancer drug resistance presents until today a major 
drawback in the management of cancer. The handling with drug resistance is aggravated by the 
facts that drug resistance is a multifactorial and multifaceted phenomenon (1). The development 
of tumor-targeted pharmacological and genetic strategies to overcome intrinsic resistance and to 
prevent the resistance acquisition is thus still a pressing need. We put forward the two main 
objectives: 1) The reversal of the pre-existing drug resistance in p53-deficient cells by either the 
concomitant abrogation of DNA repair functions or by the concomitant blocking of 
cytoprotective signaling pathways. 2) The identification of members of the novel class of 
histone deacetylase (HDAC) inhibitors with anticancer activity that have (or do not have) the 
potential to cause resistance acquisition in tumor cells. 
 Mutations in the p53 gene and dysregulation of p53-dependent cellular processes are often 
associated with cancer and resistance to radio- and chemotherapy (2-6). Many Advances have 
been taken to reconstitute the (wildtype) p53 tumor suppressor pathway in cancer cells (7). We 
showed that genetic abrogation of the expression of the DNA mismatch repair (MMR) gene 
Pms2 in cells depleted for the p53 tumor suppressor function hypersensitized these cells to the 
cytotoxic effect of some anticancer agents (see PUBLICATION I; 8) through an increase in the 
rate of apoptosis. Expanding on this, we also showed that genetic depletion of either ATM (see 
PUBLICATION II; 11), BRCA1 (12), or DNA-PK (13) resulted in an increase in the 
chemosensitivity of p53-deficient cells against a variety of anticancer agents. These studies 
indicate that tumor-targeted functional inhibition of either one or the other of these DNA repair 
genes may reverse resistance in p53-mutated tumors and therefore provide a strategy for 
increasing chemotherapy efficacy for these tumors. Analogous as well as opposing results were 
reported for loss of the MMR protein MLH1 in p53-deficient cells with Cisplatin (9,10). 
However, neither Radicicol (HSP90 inhibitor) nor LY294002 and LY294005 (Akt inhibitors) 
were found to reverse Cisplatin resistance specifically in MMR-deficient tumor cells (14,15). 
These Akt inhibitors even further decreased the sensitivity against Cisplatin, suggesting - in 
addition to its acknowledged cytoprotective function - a cytodestructive function of Akt. 
 On the other hand, we showed the potential of the HDAC inhibitor SAHA (16,17) to 
induce stable and MDR-independent resistance in HCT116 colon tumor cells (see 
PUBLICATION III; 18). As these results differ from those reported with FK-228 (17,18), we 
propose a novel mechanism of resistance acquisition by the SAHA, the nature of which is still 
obscure. This is under investigation, as is novel and intriguing molecular approach to reverse 
drug resistance: the liposomal delivery of (exogenous) cytochrome c to tumor cells. 
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 2. Introduction 
2.1. Drug resistance as a limiting factor of cancer treatment efficacy 
The management of cancer involves procedures, which include surgery, radiotherapy, 
chemotherapy, and endocrine therapy. Despite these in many cases successful therapeutic 
options, there are still drawbacks encountered by the oncologists. One of these drawbacks is 
drug resistance, which until today is a persistent problem during the treatment of local and 
disseminated diseases. Despite the large armentarium that has become available to oncologists 
during the past decades, resistance to an anticancer treatment, either present intrinsically (be 
inherent in a subpopulation of heterogeneous cancer cells) in tumor cells or acquired during a 
treatment (as a cellular response to drug exposure), is a frequently observed and persistent 
problem during the cancer treatment and thus presents a major obstacle in the fight against 
cancers. It is clear that resistance to chemotherapy limits the effectiveness of anticancer drug 
treatment. Resistance to chemotherapy is believed to cause treatment failure in over 90% of 
patients with metastatic cancer, and resistant micrometastic tumor cells may also reduce the 
effectiveness of chemotherapy in the adjuvant setting. Acquired resistance is a particular 
problem, as tumors not only become resistant to the drugs originally used to treat them but may 
also become cross-resistant to other drugs with different mechanisms of action. 
 This is not different with gynecologic cancers. Breast cancer is the most common form of 
cancer among women in North America and Europe. It is estimated that each year this disease is 
diagnosed in over one million people worldwide and is the cause of more than 400,000 deaths. 
Although chemotherapy including endocrine therapy forms part of a successful treatment 
regime in many cases, only about 50% of the patients may benefit from this, as a result of 
intrinsic or acquired multiple drug resistance or endocrine resistance (21). 
 Likewise, despite the considerable clinical efficacy of chemotherapy for primary ovarian 
cancer as well as among woman with advanced and suboptimal disease following surgery, most 
women with advanced stage of ovarian cancer would relapse, including 50% of woman who 
have no evidence of disease after primary therapy. Acquired resistance of the recurring tumor 
mass to platinum is one important factor for the poor overall prognosis for recurrent ovarian 
cancers and helps explaining why ovarian cancer remains one of the most lethal malignancies 
(22). 
 Endometrial cancer, the most common gynecologic malignancy, and cervical cancer, the 
third most common type of gynecologic cancers (but much less common in the developed 
countries due to the introduction of the Pap smear test) have excellent long-term prognoses due 
to early stage diagnosis and efficient surgical and/or radiation treatment. However, decreased 
responses to treatment and increased recurrence risk are observed in both malignancies, and the 
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 therapeutical options (adjuvant or neoadjuvant chemotherapy, surgical resection) remain limited 
(23). It is believed that chemotherapy-resistance is an important factor; in particular in HPV-
positive cervical cancers, which constitute more than 95% of cervical carcinomas, seem to have 
an inherent, HPV-associated resistance to chemotherapy-induced apoptosis (24). 
 
 
2.2. The multiple faces of drug resistance 
Drug resistance is a multifaceted phenomenon and can occur at many levels. Extensive review 
papers and books on the issue of drug resistance in cancers are available (1). Three main classes 
of resistance may be defined. Physiological resistance describes a pathophysiologic 
phenomenon characterized by the interrelationship between dysregulated angiogenesis, 
abnormal oxygenation, hypoxia and acidosis, and unstable perfusion. These factors help 
maintaining a tumor microenvironment that promotes treatment resistance and increases 
propensity for invasion and metastasis. Biological resistance is characterized by the presence of 
a subpopulation of non-curable tumor stem cells which drives cancer development and by the 
presence of a tumor microenvironment that promotes metastasis and therefore significantly 
affects the success of therapy. Parameters defining such a tumor microenvironment include the 
interactions between cell-cell interface, cell-extracellular matrix interface, and between cells 
and cytokines/soluble factors. Biochemical resistance is another well studied phenomenon. 
Principal mechanisms include altered membrane transport involving the P-glycoprotein product 
of the multidrug resistance (MDR) gene as well as other associated proteins (e.g. decreased drug 
uptake, increased drug efflux); altered drug targets (e.g. mutated drug targets such as 
topoisomerase II and tubulins); decreased drug activation, increased drug degradation, drug 
inactivation, or increased subcellular redistribution and sequestration (e.g. altered expression of 
drug-metabolizing enzymes, conjugation with increased glutathione and metallothioneins); 
enhanced DNA repair or DNA damage tolerance (e.g. loss of DNA mismatch repair MMR); 
failure to apoptose as a result of mutated cell cycle or cell suicide proteins (e.g. mutations in the 
p53 tumor suppressor gene); and covalent epigenetic modifications (DNA methylation, histone 
(de-)acetylation) leading to transcriptional silencing of genes relevant to drug responses. 
In particular, the drug resistance arisen (i) from the functional loss of the tumor suppressor 
gene p53, (ii) from mutations in the MMR genes, and (iii) the acquired resistance to histone 
deacetylase inhibitors have been in the focus in our laboratory. 
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2.3. Resistance due to dysfunction of the p53 tumor suppressor gene 
The p53 tumor suppressor gene encodes a transcription factor that regulates the expression of 
targets genes which induce cell cycle arrest, apoptosis, senescence, DNA repair or alter 
metabolism in response to a variety of stresses, including DNA damage, overexpressed 
oncogenes and various metabolic limitations (4,25-28). Inactivation of tumor suppressor genes 
can lead to a lack of proper control, especially under stress, leading to clonal outgrowth and 
tumor progression that, in turn, usually involves blockage of normally regulated cell cycle 
control and apoptosis mediated by tumor suppressor genes. Two well established consequences 
of loss of the appropriate function of p53, either by mutations or by transcriptional down-
regulation, are tumorigenesis and progression and the frequently observed reduced 
responsiveness (i.e. resistance) to genotoxic agents. 
 On the one hand, p53 is the prototype tumor suppressor gene in human cancer due to its 
pro-apoptotic and antiproliferative function in response to oncogenic stress (4,25,28,29). 
Depending on the severity of damage to the genome, p53 can activate genetic programs that halt 
cell proliferation transiently (G1 and G2 cell cycle arrest) or permanently (senescence), or 
eliminate the cell altogether (apoptosis). The p53 pathway is inactivated in the majority of 
human malignancies (2-4). Increased levels of its negative regulator MDM2 downregulate p53 
function in many of the rest (30), and therefore the p53 pathway is most likely disrupted also in 
a large fraction of wild-type p53-carrying tumors. Li-Fraumeni syndrome is an inherited cancer 
predisposition caused by p53 mutations, giving rise to early onset of cancers (31). p53 also 
plays a role in inflammatory responses and in non-neoplastic diseases (32). 
 On the other hand, the p53-status of the tumor is an important determinant of the 
sensitivity of tumors to genotoxic agents. p53 mutations or inactivation of its function often 
associate with chemoresistance in tumors, e.g. against antracyclines, antimetabolites, and 
cisplatin (5,6,33). In the last decade much effort has been taken to reconstitute the p53 tumor 
suppressor pathway in cancer cells (7). Despite some promising advances, the list of p53-based 
therapeutic strategies under preclinical development is growing and novel p53-based therapeutic 
strategies may also be combined with conventional cancer therapy. 
 
 
2.4. Resistance as a consequence of loss of DNA mismatch repair function 
The DNA mismatch repair (MMR) system functions in the elimination of biosynthetic errors 
that arise during DNA replication, in DNA damage surveillance, and in the prevention of 
recombination between non-identical sequences. It therefore substantially contributes to the 
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 maintenance of genome integrity (34-37). It is thus not surprising that loss of MMR function 
may lead to cancer (38-40). Inherited defects due to germline mutations in the MMR genes 
underlie the hereditary non-polyposis colon cancer (HNPCC) syndrome in humans, and 
epigenetic silencing of the hMLH1 gene accounts for sporadic cancers, including those of the 
endometrium and ovaries. Even more important, another hallmark of MMR is its capacity to 
elicit DNA damage-induced cell death (41). Although this might seem to make MMR a useful 
target for anticancer agents, it has become clear that tumor cells with defective MMR can 
display reduced sensitivity to DNA damaging agents. This was in fact the case with some types 
of DNA damaging agents (42). Previous studies, including those by our own laboratory (18,43-
47) have identified a variety of commonly used anticancer agents against which MMR-deficient 
tumor cells are resistant, including the alkylating agents Temozolomide and Busulfan, the 
platinum compounds Cisplatin, Carboplatin, and Lipoplatin (liposomal Cisplatin; Regulon Inc., 
Mountain View, CA), the topoisomerases I poisons Camptothecin and Topotecan, the 
topoisomerase II poisons Doxorubicin, Epirubicin, Mitoxantrone, and Etoposide, and the 
antimetabolites 5-Fluorouracil and 6-Thioguanine. In addition and not less important, anticancer 
agents and a light-based therapy were also identified against which these cells retain sensitivity. 
These include the taxanes Docetaxel and Paclitaxel, the platinum-derivative Oxaliplatin and its 
liposomal formulation Lipoxal (Regulon Inc., Mountain View, CA), the DNA minor groove 
binder Brostallicin, the histone deacetylase (HDAC) inhibitors SAHA, Trichostatin A, and 
Valproate, and the photodynamic therapy. Chemoresistance due to loss of MMR would predict 
reduced therapeutic efficacy in the treatment of these tumors, and this is even exacerbated by 
the potential of some agents to cause de novo generation of MMR-resistant variants (48). 
Although still on debate, the potential clinical relevance of this usually moderate degree (2 to 4-
fold) of resistance has been demonstrated in clinical studies (49-51). 
 
 
2.5. Resistance to histone deacetylase inhibitors 
Histone deacetylase (HDAC) inhibitors are a relatively novel and promising class of potent 
anticancer agents, as they have strong anticancer properties and show promising results with 
respect to efficacy and tolerability (52-55). By affecting gene expression, HDAC inhibitors, 
either by themselves or in combination with other anticancer agents, induce cell cycle arrest and 
apoptosis specifically in tumor cells (56-58). They also counteract invasion, vascularization, and 
angiogenesis (59). 
 Vorinostat (SAHA, Zolinza) is one of the lead compounds and is the first of the new 
HDAC-inhibitors to be approved by Food and Drug Administration for the clinical use in cancer 
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 patients, namely the treatment of cutaneous T-cell lymphoma (CTCL) (16,60-62). Vorinostat is 
currently tested in more than 30 clinical trials. At least 14 different HDAC-inhibitors (e.g. 
LBH589, FK-228, MS-275, Valproic acid) are in clinical trials as monotherapy or in 
combination in patients with hematologic and solid tumors.  
 However, resistance to HDAC-inhibitors has also been observed in preclinical studies 
(17,63,64) and even in clinical trials (61). The basis of resistance is not well understood, but 
overexpression of anti-apoptotic Bcl-2 (65), of thioredoxin (66), of the ROS-reducing 
peroxiredoxin (67), and of MDR may play a role (68). Moreover, the HDAC-inhibitor FK-228 
(depsipeptide) induced reversible expression of MDR in tumor cells, rendering them transiently 
resistant to FK-228 (19,20). This suggests the potential of HDAC inhibitors to induce 
resistance. Whereas the mode of action of HDAC inhibitors has been intensively studied (58), 
the mechanisms of resistance is much less understood. 
 
 
2.6. Prevention, circumvention, and reversal of drug resistance 
The development of pharmacological and genetic strategies to overcome intrinsic resistance and 
the prevention of resistance acquisition during chemotherapy are a pressing need for researchers 
and oncologists. However, this is often compromised by the fact that drug resistance is a 
multifactorial and multifaceted phenomenon that is characterized by the physiology and the 
microenvironment of the tumor, by the efficacy of drug delivery to the tumor, by the drug 
activation/inactivation and the availability of the drug target in the tumor, and perhaps also by 
the different clinicopathological characteristics of different subgroups of patients. 
 Drug resistance may not be restricted to a certain (chemical) class of anticancer agents but 
could be observed for almost any molecule with anticancer activity. With the development of 
novel and efficient anticancer agents, researches and oncologists should consider the possibility 
that a novel and promising anticancer agent could potentially turn out to be associated with 
reduced responsiveness against some but not other tumor types and/or with a certain 
subpopulation of cancer patients, and hence to be an inducer of a stable drug resistance 
phenotype. Great efforts are being taken to identify cancer-relevant molecular targets that can be 
targeted by potent molecules with a high antitumor activity. In addition to the anticancer agents 
already widely and successfully used for cancer treatment, a variety of novel classes of potential 
targets and anticancer agents arose in the last decade. 
 Approaches to handle with drug resistance in tumor cells mainly include the following 
strategies: i) the use of combination drug therapy using different classes of drugs with 
minimally overlapping toxicities to allow maximal dosages and with narrowest cycle intervals; 
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 (ii) the identification of anticancer agents to which tumor cells are intrinsically resistant and 
therefore may not be used for therapies; iii) the identification of anticancer agents that retain 
sensitivity also in drug-resistant cells (i.e. no cross-resistance) and therefore may be suitable for 
a therapy; iv) the application of molecular (genetic and pharmacologic) strategies that reverse 
the drug-resistance phenotype either by further increasing cellular stress or by downregulating 
cytoprotective functions; v) the identification of anticancer agents that have the potential to 
cause acquisition of resistance in initially sensitive tumor cells (and of those which don’t) and 
therefore may (or may not) compromise a therapy. 
With our interest in establishing novel and clinically applicable strategies to cope with 
drug resistance in tumor cells, we became increasingly interested in both genetic and 
pharmacological strategies that reverse (pre-existing) drug resistance on the one hand and in the 
identification of novel and potential anticancer agents that result – or that do not result - in the 
development (acquisition) of a drug resistance phenotype in tumor cells on the other. The 
former is of increasing interest, because to date no clinically suitable compounds has been 
identified to which preferentially MMR-deficient (but not MMR-proficient) tumor cells are 
hypersensitive. Likewise, despite the promising achievements in restoring wildtype p53 function 
in (resistant) tumors, there is still potential to be fully tapped in this regard. 
With regard to the reversal of the (pre-existing) drug resistance phenotype arisen either by 
loss of p53 function or by loss of MMR function, we put forward the two following strategies: 
(i) the reversal of p53 defect-associated resistance through the genetic abrogation of MMR 
function on the one hand (2.6.1) and of DNA double-strand break repair on the other (2.6.2); (ii) 
the reversal of MMR defect-associated resistance through the pharmacological blocking of 
cytoprotective signaling pathways (2.6.3). 
With regard to the prevention of resistance development, the strategy has been put 
forward that aimed at identifying members of the relatively novel class of potential anticancer 
agents (the HDAC inhibitors) that either could or could not lead to development of a resistance 
phenotype in tumor cells (2.6.4). 
 
 
2.6.1. Reversal of drug resistance in p53-null cells by genetic deletion of the Pms2 DNA 
mismatch repair gene 
It is generally acknowledged that cells with defective p53 function or defective MMR exhibit 
reduced responsiveness to some genotoxic agents. Thus, one might think that both defects 
present in the cell at the same time would result in an even higher magnitude of resistance. Or 
one might think that the absence of proper repair of mismatched DNA introduced by genotoxic 
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 agents (due to loss of MMR) combined with the failure to properly induce cell cycle checkpoint 
and apoptosis activation (due to loss of p53 function) in the presence of DNA damage would 
cause the cell to become highly sensitive to the DNA damaging agent, i.e. would lead to 
reversal of drug resistance in p53-deficient cells. This latter idea was pursued. The strategy was 
to achieve hypersensitivity and drug resistance reversal in (chemoresistant) p53-deficient cells 
through the additional (genetic) deletion of the function of the MMR gene Pms2. 
Indeed, we were able to show (see PUBLICATION I, 8) hat loss of the MMR protein 
Pms2 in p53-deficient cells results in hypersensitivity to the anticancer agents Cisplatin, 
Doxorubicin, Etoposide, Docetaxel and Gemcitabine. Moreover, this hypersensitizing effect 
resulting from Pms2 loss correlated with increased apoptosis but not with alterations in cell 
cycle checkpoint control. These results indicated that p53-deficient (resistant) tumor cells can be 
re-sensitized to anticancer agents by the concurrent loss of one specific type of DNA repair 
function, i.e. MMR-function. This suggests that tumor cells which are defective in both 
functions at the same time are more chemosensitive than the cells defective in p53 alone. It 
therefore seems that Pms2 is a positive modulator of cell survival in p53-deficient cells (as 
opposed to its cell death-inducing property in p53-wildtype cells), although the molecular basis 
of this hypersensitizing effect is not fully understood. Analogous results were reported for loss 
of the MMR protein MLH1 in p53-deficient cells with Cisplatin (9). However, opposing data 
were also reported in a recent study (10): cells deficient in MLH1 and p53 function were even 
more resistant than cells deficient in either one or the other function, and this correlated with 
enhanced mutagenic translesion synthesis and increased homologous recombination. 
 
2.6.2. Reversal of drug resistance in p53-null cells by genetic deletion of DNA double-
strand break repair genes 
The aforementioned results with the Pms2/p53 doubly-deficient cells prompted us to 
incorporate the strategy of “double-impact” into a more general concept. Accordingly, we 
proposed that p53-deficient (chemoresistant) tumor cells could be re-sensitized to DNA 
damaging agents through the additional loss of their ability to properly repair anticancer agents-
introduced DNA damage. The idea behind this was that cells accumulate high levels of 
irreparable DNA damage (due to reduced repair) and at the same time fail to properly respond 
(i.e. halting cell cycle progression and allowing for repair) to the presence of this damaged DNA 
due to the lack of p53 function, finally leading to extensive and rapid cell death. 
One of the target genes was ATM (Ataxia Telangiectasia Mutated). The ATM gene is 
mutated in patients with ataxia telangiectasia, an autosomal recessive genetic disorder 
characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, 
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 radiohypersensitivity, and increased risk of malignancies including breast cancer (69). ATM 
also play a central role in the repair of DNA double-strand break in that it is recruited to sites of 
DNA damage (and thus acts as DNA damage sensor) where it initiates a signaling cascade 
through phosphorylation of multiple DNA damage response and cell cycle proteins (70). 
In line with our proposal, we were able to show that ATM/p53 doubly-deficient cells are 
hypersensitive to the topoisomerase I poisons Camptothecin and Topotecan, to the 
topoisomerase II poisons Doxorubicin, Epirubicin, and Etoposide, and to the antimetabolites 5-
Fluorouracil and Gemcitabine, as compared to ATM-expressing p53-deficient counterparts (see 
PUBLICATION II; 11). This hypersensitizing effect correlated with increased necrosis rather 
than with increased apoptosis and additional cell cycle alterations. We thus conclude that the 
concomitant loss of the ATM function increases the sensitivity of p53-deficient cells to these 
anticancer agents, and that tumor-targeted functional inhibition of ATM may provide a valuable 
strategy for increasing the efficacy of anticancer agents in the treatment of p53-mutant and 
chemoresistant cancers. No hypersensitization was observed with Cisplatin, Carboplatin, 
Oxaliplatin, Docetaxel, and Paclitaxel. 
We speculated that this hypersensitizing effect may not be restricted to the loss of the 
ATM function, and in fact we found that this strategy applied also to the loss of BRCA1 (12) or 
DNA-PK (13) in p53-deficient cells. The BRCA1 (Breast Cancer Type 1 Susceptibility) protein 
is important in maintaining genomic stability by promoting efficient and precise repair of 
double-strand breaks and by mediating signal transduction to a variety of downstream events 
(cell cycle checkpoint control and apoptosis induction) upon DNA damage thought the 
interaction with many other repair and repair-associated proteins (71). Carriers of heterozygous 
mutations in BRCA1 are strongly predisposed to breast and ovarian cancers (72,73). DNA-PK 
(DNA-Dependent Protein Kinase) belongs to the PI3-K related kinase family, is involved in the 
non-homologous end joining (NHEJ) process that corresponds to the major activity responsible 
for cell survival after ionizing radiation or chemotherapeutic treatment producing DNA double 
strand breaks, and is believed to be a molecular sensor for DNA damage that enhances the 
signal via phosphorylation of many downstream targets (74). Despite the function of DNA-PK 
in the protection from genomic instability, its role in cancer prevention is still unclear (75). 
 
2.6.3. Reversal of drug resistance in MMR-deficient cells by pharmacological blocking 
cyto-protective signaling pathways 
The other strategy was to achieve re-sensitization of MMR-deficient, Cisplatin-resistant colon 
tumor cells through the concomitant downregulation of cytoprotective signaling pathways by 
means of target-specific small molecule inhibitors against key factors of these pathways. It was 
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 anticipated that this would overrule the drug-resistance phenotype. Two targets have been 
focused on: the heat shock protein HSP90 and the Akt protein kinase. 
HSP90 is a molecular chaperone required for the stress-survival response, protein 
refolding, and the conformational maturation of a variety of signaling proteins. An association 
of HSP90 overexpression and cancer has been proposed, and HSP90 inhibitors have antitumor 
activity when given alone and in combination with cytotoxics (76,77). We were able to show 
that the inhibition of the HSP90-function by Radicicol re-sensitizes (Cisplatin-resistant) MMR-
deficient cells to Cisplatin; but this re-sensitizing effect was also observed to even a greater 
extent for the corresponding MMR-proficient cells (14). We therefore conclude that the HSP90 
inhibitor Radicicol sensitizes cells to Cisplatin and that the presence of MLH1 even aggravates 
this sensitizing, suggesting that HSP90-inhibition does indeed increase the cytotoxic effect of 
Cisplatin but that it is not a suitable way to render in particular Cisplatin-resistant cells 
hypersensitive to Cisplatin. 
 The Akt protein kinase transduces signals from growth factors and oncogenes to 
downstream targets that control crucial elements in tumor development. The Akt pathway is one 
of the most frequently hyperactivated signaling pathways in human cancers, and therefore 
down-regulation of this pathway may be a viable strategy to prevent cancer (78,79). Rather 
unexpectedly, we found that inhibition of the proliferative Akt-signaling pathway by the novel 
Akt-specific inhibitor LY294005 decreased (rather than increased) Cisplatin and Lipoplatin 
sensitivity in both MMR-deficient and MMR-deficient cells and that this effect occurred to a 
greater extent and hence preferentially with MMR-deficient cells (15). Lipoplatin is a novel 
liposomal formulation of Cisplatin to which MMR-deficient cells are also resistant (46). These 
results appear not consistent with our concept of drug resistance reversal. Instead, a perhaps 
novel function of the protein kinase Akt was uncovered (at least with platinum compounds) 
which seems to increase rather than decrease cell survival. The molecular basis is still unclear 
and is subject to further investigation in our laboratory. 
 
2.6.4. Acquired resistance to HDAC-inhibitors and its prevention 
With regard to the apparently only limited availability of clinically applicable strategies to 
circumvent or even reverse the drug resistance phenotype seen in tumor cells, the prevention of 
drug resistance development by anticancer agents is of increasing interest. In other words: the 
generation of drug-resistant variants during the treatment of initially drug-sensitive tumor cells 
with anticancer agents should be prevented (acquisition of resistance). This means that each 
novel and potential anticancer agent should be subject to testing whether it has drug resistance-
causing potential. In this respect, we showed that the novel HDAC-inhibitor SAHA can induce 
 10
 moderate and MDR-independent resistance in tumor cells (see PUBLICATION III; 18), 
suggesting that SAHA is a potential inducer of drug resistance. In addition, these SAHA-
resistant cells were also cross-resistant to the HDAC-inhibitors TSA and VPA, but retained 
sensitivity to conventional anticancer agents such as Docetaxel, Cisplatin, and Temozolomide. 
These results expand on recent findings by two other groups that the HDAC-inhibitor FK-228 
also induces resistance in tumor cells but in a reversible and MDR-dependent manner (19,20). 
However, the molecular basis of this putatively novel type of acquired resistance is still unclear 
and is thus subject to current investigation in our laboratory. Although not conclusive at this 
point in terms of clinical relevance, this resistance-inducing potential of (at least some) HDAC-
inhibitors and the associated cross-resistance may be kept in mind prior the use in for cancer 
treatment. At least, the data suggest that HDAC inhibitor-resistant tumors may be treated with 
conventional anticancer agents. Moreover, the identification of HDAC-inhibitors (as well of 
other anticancer agents) that do not cause development (acquisition) of resistance in tumor cells 
is an important issue in this context. 
 11
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Increased sensitivity of p53-deficient cells to anticancer agents
due to loss of Pms2
A Fedier1, UB Ruefenacht1, VA Schwarz1, U Haller1 and D Fink*,1
1Department of Obstetrics and Gynaecology, Division of Gynaecology, University Hospital of Zurich, CH-8091, Switzerland
A large fraction of human tumours carries mutations in the p53 gene. p53 plays a central role in controlling cell cycle
checkpoint regulation, DNA repair, transcription, and apoptosis upon genotoxic stress. Lack of p53 function impairs these
cellular processes, and this may be the basis of resistance to chemotherapeutic regimens. By virtue of the involvement of
DNA mismatch repair in modulating cytotoxic pathways in response to DNA damaging agents, we investigated the effects of
loss of Pms2 on the sensitivity to a panel of widely used anticancer agents in E1A/Ha-Ras-transformed p53-null mouse
fibroblasts either proficient or deficient in Pms2. We report that lack of the Pms2 gene is associated with an increased
sensitivity, ranging from 2 – 6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin,
etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the
antimetabolite gemcitabine. In contrast, no change in sensitivity was found after treatment with 5-fluorouracil. Cell cycle
analysis revealed that both, Pms2-deficient and -proficient cells, retain the ability to arrest at the G2/M upon cisplatin
treatment. The data indicate that the concomitant loss of Pms2 function chemosensitises p53-deficient cells to some types of
anticancer agents, that Pms2 positively modulates cell survival by mechanisms independent of p53, and that increased
cytotoxicity is paralleled by increased apoptosis. Tumour-targeted functional inhibition of Pms2 may be a valuable strategy for
increasing the efficacy of anticancer agents in the treatment of p53-mutant cancers.
British Journal of Cancer (2002) 87, 1027 – 1033. doi:10.1038/sj.bjc.6600599 www.bjcancer.com
ª 2002 Cancer Research UK
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The tumour suppressor gene p53 plays a central role in controlling
cell cycle checkpoint regulation, DNA repair, transcription, and
apoptosis upon genotoxic stress. p53 is one of the most frequently
mutated genes in human cancers and plays a critical role in the
regulation of cell cycle and apoptosis (Levine, 1997). A number
of studies have suggested that loss of p53 function may be a major
reason underlying failure to respond to chemotherapy (Ferreira et
al, 1999). Evidence for this notion is emerging from studies of
established human cancer cell lines and from knockout mice
models.
DNA mismatch repair (MMR) proteins play an important role
in the maintenance of genomic stability since it corrects replicative
mismatches that escape DNA polymerase proofreading. Loss of
MMR results in genomic instability characterised by small insertion
and deletion mutations in repetitive sequences throughout the
genome. As well as being involved in carcinogenesis, loss of the
MMR activity is of concern with respect to the use of chemother-
apeutic agents to treat established tumours. Loss of MMR has been
reported to cause resistance to some types of anticancer agents
including cisplatin (Fink et al, 1996) and the topoisomerase II
poisons (Fedier et al, 2001). Interestingly, loss of MLH1 function
has recently been reported to result in an increased sensitivity to
cisplatin in p53-mutated human colorectal adenocarcinoma cells
(Vikhanskaya et al, 1999; Lin et al, 2001). However, the cell lines
used in these previous studies were not truly isogenic, since in
order to restore MMR activity, a whole copy of chromosome 3
carrying a wild-type copy of MLH1 was inserted into the
HCT116 cells. Thus, it is conceivable that the differences in cispla-
tin sensitivity observed in these cell lines could have been due to
one of the many genes on the inserted chromosome other than
the wild-type copy of the missing MMR gene. So far no informa-
tion is available on the effect of loss of PMS2, another MMR gene,
to chemotherapeutic agents in p53-deficient cells.
Using transformed primary fibroblasts established from E1A/Ha-
Ras-transfected knockout mice, we report here that p53-deficient
cells are sensitised to some anticancer agents by the additional loss
of the Pms2 gene, indicating that Pms2 positively regulates cell
survival by a p53-independent mechanism. Tumour-targeted func-
tional inhibition of Pms2 may thus be an adjunct to anticancer
agents in the treatment of p53-mutant cancers.
MATERIALS AND METHODS
Cell lines
The Pms27/7/p537/7 and Pms2+/+/p537/7 cell lines, established
from E1A/Ha-Ras-transformed knockout mice primary fibroblasts,
were generously provided by Dr PM Glazer (Zeng et al, 2000).
These primary fibroblasts have been produced by breeding mice
heterozygous for Pms2 to either wild-type or p53-null mice, and
then by intercrossing progeny animals to generate mice either
wild-type or null for Pms2 in a p53-nullizygous background. The
cells were maintained in DMEM medium supplemented with
2 mM L-glutamine (Life Technologies, Basel, Switzerland), 10%
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heat inactivated foetal calf serum (Oxoid, Basel, Switzerland) and
penicillin/streptomycin (100 U ml71/100 mg ml71, Life Technolo-
gies) at 378C in a humidified atmosphere containing 5% carbon
dioxide. The Pms27/7/p537/7 cells as well as the Pms2+/+/p537/7
cells form defined individual colonies when seeded sparsely on
standard culture dishes. All the cell lines tested negative for
contamination with Mycoplasma spp.
Reagents
The following drugs were generous gifts: docetaxel (Aventis,
Zurich, Switzerland), cisplatin, etoposide and paclitaxel (Bristol-
Myers Squipp, Baar, Switzerland), mitoxantrone (Lederle, Zug,
Switzerland), doxorubicin (Pharmacia & Upjohn, Dubendorf, Swit-
zerland), 5-fluorouracil (Roche, Reinach, Switzerland), gemcitabine
(Eli Lilly, Vernier, Switzerland), and oxaliplatin (Sanofi-Synthelabo,
Meyrin, Switzerland).
Antiproliferative and cytotoxicity assays
Cisplatin, oxaliplatin, doxorubicin, mitoxantrone and 5-fluoroura-
cil were dissolved immediately before use in 0.9% NaCl solution.
Etoposide and paclitaxel were prepared in DMSO, whereas doce-
taxel was dissolved in methanol. The final concentration of
DMSO or methanol in the cultures was 50.1% at all drug concen-
trations and in controls. Previous experiments (data not shown)
have shown that neither 0.1% DMSO nor 0.1% methanol affects
the viability or growth of these cell lines.
The antiproliferative effect in response to drug treatment was
determined by the colorimetric MTT-assay (Mosmann, 1983).
Briefly, cells growing in the log phase were harvested by brief tryp-
sinisation and washed once with medium containing 10% foetal
calf serum. Using 96 well plates, 1000 cells were plated 24 h prior
to incubation with or without the drug for 72 h at 378C in a humi-
dified atmosphere containing 5% carbon dioxide. A volume of
20 ml MTT in PBS to a final concentration of 0.5 mg ml71 was
added, followed by incubation at 378C for 4 h, aspiration of the
medium, and addition of 200 ml DMSO. Optical density was
measured by the Emax microplate reader E9336 (Molecular Devices,
Clearwater, MN, USA) at 540 nm setting the value of the cell lines
in medium to 1.0 (control) and the value of the no cells blank to
zero. Differences in drug sensitivity of the respective cell lines were
determined from at least four independent experiments with
continuous drug exposure and are reported as the concentration
required to suppress proliferation by 50% (IC50).
In addition, one member of each drug class was tested for cyto-
toxic effects by means of colony forming assay and trypan blue
exclusion assay. Clonogenic survival in response to drug treatment
was performed by plating 1000 cells in 60 mm cell culture dishes.
After 24 h, the drug was added, followed by incubation for 6 days
at 378C in a humidified atmosphere containing 5% carbon dioxide.
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Figure 1 Antiproliferative effect to a continuous exposure to cisplatin,
oxaliplatin, doxorubicin, etoposide, docetaxel, and 5-fluorouracil for
Pms2+/+/p537/7 and Pms27/7/p537/7 cells as determined by the
MTT-assay. Each point represents the mean+s.d. of at least four indepen-
dent experiments.
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Figure 2 Clonogenic survival curves in response to a continuous expo-
sure to cisplatin, doxorubicin, docetaxel, and 5-fluorouracil for the Pms2+/
+/p537/7 and the Pms27/7/p537/7 cell lines. Each point represents the
mean+s.d. of at least four independent experiments.
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Cells were fixed with 25% acetic acid in ethanol and stained with
Giemsa. Colonies of at least 50 cells were scored visually. Each
experiment was performed a minimum of four times using tripli-
cate cultures for each drug concentration. The logarithm of relative
colony formation was plotted against the concentration of the
drug. The IC50 was estimated by linear interpolation of the loga-
rithmic transformed relative plating efficiencies. For trypan blue
exclusion assay, cells were grown to 60% confluence and incubated
with or without the drug for 24 h, 48 h or 72 h. At the time points
indicated, floating and adherent cells were collected. Cells were
then incubated with trypan blue solution at 0.1% final concentra-
tion for 1 min, and the number of trypan blue-positive and
-negative cells was determined using a haematocytometer.
TUNEL apoptosis assay
Cells were grown to 70% confluence in 60 mm dishes in triplicate
cultures and then treated with 5 mM cisplatin. Adherent and float-
ing cells were collected at the time points indicated and washed in
PBS. Cells were then fixed by dropwise addition of ice-cold 70%
ethanol. Samples were stored at 48C until further use. Samples
were washed twice with PBS and resuspended in the TUNEL
reaction mixture and incubated at 378C for 2 h, according to the
manufacturer’s protocol (Roche Molecular Biochemicals, Basel,
Switzerland). Cells were analysed by flow cytometry (EPICS ELITE,
Beckmann-Coulter, Hialeah, FL, USA).
Cell cycle analysis
Cells were grown to 70% confluence in 60 mm dishes in triplicate
cultures and then incubated with or without cisplatin (1.0 mM).
This drug concentration induces about a 70% growth inhibition
of Pms2-deficient cells in the MTT-assay and about a 95% reduc-
tion of clonogenic survival. Cells were then harvested by brief
trypsinisation and washed once in ice-cold PBS. The pellet was
resuspended in 200 ml PBS and cells were fixed by dropwise addi-
tion of 4 ml ice-cold 70% ethanol and then stored at 48C until use.
After removing ethanol by centrifugation at 30006g and washing
twice in PBS, cells were stained in 1 ml of propidium iodide stain-
ing solution (50 mg ml71 propidium iodide and 100 U ml71
RNAse A in PBS) by incubation at room temperature for 60 min
in the dark and then washed once in PBS containing 0.2% BSA.
Samples were analysed for their DNA content by flow cytometry
(EPICS ELITE, Beckmann-Coulter, Hialeah, FL, USA), and the
percentage of cells in each phase was determined using the Multi-
Cycle for Windows Software (Phoenix Flow Systems, San Diego,
CA, USA).
Statistical analysis
Mean+s.d. values were calculated for all data sets. The two-sided
paired t test was used to compare the effects of loss of Pms2 func-
tion on drug sensitivity. P50.05 was considered to be a statistically
significant difference.
RESULTS
Growth inhibition of Pms2+/+/p537/7 and Pms27/7/
p537/7 cells after treatment with anticancer agents
We addressed the question as to whether the concomitant loss of
Pms2 function in p53-deficient cells is associated with changes in
sensitivity to a panel of clinically relevant anticancer agents. The
presence or absence of p53 and Pms2 in the respective cell lines
was verified by immunoblot analysis.
The antiproliferative effect of the platinum compounds cisplatin
and oxaliplatin, the topoisomerase II poisons doxorubicin, mitox-
antrone and etoposide, the taxanes docetaxel and paclitaxel, and
the antimetabolites 5-fluorouracil and gemcitabine was tested in
cell lines proficient or deficient in Pms2 in a setting of p53 nulli-
zygosity. Figure 1 shows the antiproliferative effect to a continuous
exposure to cisplatin, oxaliplatin, doxorubicin, etoposide, docetaxel
and 5-fluorouracil for Pms2+/+/p537/7 and Pms27/7/p537/7 cells
as determined by the MTT-assay. The Pms2-deficient Pms27/7/
p537/7 cells were 6.4-fold more sensitive to cisplatin
(0.7+0.3 mM vs 4.7+0.6 mM, P=0.0002), 2.5-fold more sensitive
to oxaliplatin (1.4+0.2 mM vs 3.5+1.1 mM, P=0.03), 5.3-fold more
sensitive to doxorubicin (13.9+2.2 nM vs 73.4+18.8 nM,
P=0.002), 3.0-fold more sensitive to mitoxantrone (2.7+0.8 nM
vs 8.1+1.8 nM, P=0.005), 6.1-fold more sensitive to etoposide
(17+3 nM vs 105+30 nM, P=0.01), 4.8-fold more sensitive to
docetaxel (13+2 nM vs 64+13 nM, P=0.0005), 4.3-fold more
sensitive to paclitaxel (15+4 nM vs 66+14 nM, P=0.004), and
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Figure 3 Sensitivity to cell kill of Pms27/7/p537/7 (open field)
and Pms2+/+/p537/7 (closed field) cells in response to cisplatin (3 mM),
doxorubicin (50 nM) or 5-fluorouracil (5 mM) as a function of time deter-
mined by trypan blue exclusion. Each point represents the mean+s.d. of
at least four independent experiments.
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Figure 4 Representative cell cycle phase distribution profile of the DNA content for Pms2+/+/p537/7 cells (left panel) and Pms27/7/p537/7 cells (right
panel) as a function of time (0 h, 24 h, 48 h, 72 h) in response to treatment with 1.0 mM cisplatin. 2N represent cells accumulated in G1, 4N represent cells
accumulated in G2/M.
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5.5-fold more sensitive to gemcitabine (39+21 nM vs 213+65 nM,
P=0.001) as compared to the Pms2+/+/p537/7 cells. In contrast, no
difference in sensitivity was found for 5-fluorouracil (1.5+0.2 mM
vs 1.7+0.6 mM, P=0.43). Thus, our data indicate that the concomi-
tant loss of Pms2 in p53-deficient cells results in a hypersensitivity
to platinum compounds, topoisomerase II poisons, taxanes, and
gemcitabine.
Clonogenic cell survival and trypan blue exclusion assays
Colorimetry-based short-term cytotoxicity assays such as the
MTT-assay may underestimate overall cell killing owing to the
notion that cells may not die immediately after treatment but
may instead remain in a transient state of arrest for several days
prior to dying (Brown and Wouters, 1999). Therefore, the clono-
genic assay was performed for one member of each drug class in
addition to the MTT-assay. Figure 2 shows the survival curves for
the Pms2-proficient Pms2+/+/p537/7 cell line as well as the
repair-deficient Pms27/7/p537/7 cell line as a function of drug
concentration. In comparison to the Pms2+/+/p537/7 cell line
the Pms2-deficient Pms27/7/p537/7 cell line was 1.6-fold more
sensitive to cisplatin (0.68+0.10 mM vs 0.41+0.07 mM, P=0.002),
1.7-fold more sensitive to doxorubicin (12.1+1.4 nM vs
7.3+0.4 nM, P=0.004) and 1.8-fold more sensitive to docetaxel
(7.5+1.0 nM vs 4.0+0.2 nM, P=0.005). In contrast, no difference
in sensitivity was observed in response to 5-fluorouracil
(0.57+0.06 mM vs 0.63+0.07 mM, P=0.25). Thus, the clonogenic
survival data support the results observed in the MTT-assay,
indicating that loss of Pms2 function in p53-deficient cells
decreases clonogenic survival to these agents.
The trypan blue exclusion assay demonstrates that Pms2-defi-
cient cells have a substantially higher percentage of trypan blue-
stained cells than Pms2-proficient cells in response to equi-antipro-
liferative doses (i.e. doses that inhibited proliferation by 90% in
Pms2-deficient cells) of doxorubicin (50 nM) or cisplatin (3 mM)
at each time point after treatment (Figure 3). This effect, however,
is not observed in response to 5-fluorouracil (5 mM). These data
indicate that Pms2 deficiency reduces the threshold for cell kill
to doxorubicin and to cisplatin, but not to 5-fluorouracil. Thus,
the higher sensitivity to cell kill of Pms2-deficient cells to doxoru-
bicin or cisplatin confirms the increased antiproliferative effect and
the decreased clonogenic survival of these cells to these agents.
Pms2-deficiency and cisplatin-induced apoptosis
Using cisplatin as a representative of compounds that display
hypersensitivity in clonogenic survival as well as in proliferation
inhibition, the TUNEL apoptosis assay was performed to determine
whether the increased sensitivity to cisplatin due to loss of Pms2
function was accompanied by increased apoptosis. Treatment with
5 mM cisplatin, which inhibited growth of Pms2-deficient cells by
more than 95%, produced more apoptotic Pms27/7/p537/7 cells
than Pms2+/+/p537/7cells. The respective values were 37+5% vs
5+1% at 30 h after cisplatin treatment and 43+4% vs 20+14%
at 60 h after treatment. These results indicate that the hypersensi-
tivity to the cytotoxic effect of cisplatin in Pms2-deficient cells is
associated with increased apoptosis.
Cell cycle analysis of Pms2+/+/p537/7 and
Pms27/7/p537/7 cells after treatment with cisplatin
The question was addressed as to whether the increased sensitivity
to, for instance, cisplatin in p53-deficient cells is accompanied by
alterations in triggering cell cycle checkpoint activation. Cisplatin
has been shown to be a potent inducer of MMR-dependent
G2/M arrest (Brown et al, 1997). Figure 4 shows that 1 mM
cisplatin, which inhibited growth of Pms2-deficient cells by 70%
in the MTT-assay, resulted in response to cisplatin in a sustained
accumulation at the G2/M transition of Pms2-proficient and
-deficient cells. The data demonstrate that both Pms2-proficient
and -deficient cells retain the ability to arrest at the G2/M
upon cisplatin treatment. Thus, the observed hypersensitivity in
Pms2-deficient cells seems not to be accompanied by alterations
in the characteristic changes in cell cycle distribution profile
induced by drug treatment.
DISCUSSION
The present study indicates that p53-null mouse fibroblasts are
rendered hypersensitive to cell killing in response to platinum
compounds, topoisomerase II poisons, taxanes and the antimetabo-
lite gemcitabine by the concomitant loss of Pms2 function, and
that both Pms2-deficient and -proficient cells retain the ability to
arrest at G2/M upon cisplatin treatment. This observation is impor-
tant for several reasons: First, it identifies PMS2 as another putative
protective mediator of cell survival in p53-deficient cells, and it
thus expands on the previous finding reporting increased sensitivity
to cisplatin by the concomitant loss of MLH1 function (Vikhans-
kaya et al, 1999; Lin et al, 2001). Second, it identifies, in
addition to the platinum compounds, two other clinically impor-
tant classes of anticancer agents that result in hypersensitivity in
p53-deficient cells by the additional loss of MMR. Third, it further
supports the notion that MMR proteins such as PMS2 or MLH1
(Vikhanskaya et al, 1999; Lin et al, 2001) modulate protective
DNA damage response pathways independently of p53 function.
This finding supports the concept of a novel role of MMR, in addi-
tion to mediating drug-induced cytotoxicity (Fink et al, 1998;
Fedier et al, 2001), as a positive modulator of cell survival after
DNA damage. A precedent for this hypothesis has already been
found as it has been reported that MLH1-deficiency is associated
with hypersensitivity to mitomycin C in p53-proficient cells
(Fiumicino et al, 2000). Fourth, the observed hypersensitivity of
Pms2-deficient cells seems to be independent of the cell cycle
and seems to be due to increased apoptosis. The observed p53-
independence of cytotoxicity goes along with the previous observa-
tion that MMR can trigger apoptosis in a p53-independent
pathway (Zeng et al, 2000).
Mutations that disable p53 are frequently found in human
cancers (Hollstein et al, 1991), often in association with tumour
progression or high grade malignancy (Carder et al, 1993). There-
fore, much effort has gone into determining the effects of p53
inactivation on the response of cancer cells to therapeutic agents.
The results vary with the cell line under study and the experimental
set-up, and thus both decreased and increased sensitivities have
been observed in different model systems (Blandino et al, 1999;
Bunz et al, 1999). Recently, it has been reported that loss of
MLH1 is associated with a hypersensitivity to cisplatin in p53-defi-
cient cells in the HCT116 model (Vikhanskaya et al, 1999; Lin et al,
2001). However, the repair-deficient member of these cell lines was
not truly isogenic since in order to restore MMR activity a whole
copy of chromosome 3 carrying a wild-type copy of MLH1 was
inserted into the HCT116 cells (Koi et al, 1994). The present study
uses isogenic primary fibroblasts established from E1A/Ha-Ras-
transfected knockout mice. These cells are genetically well defined
and therefore constitute a more meaningful test system than
cancer-derived cell lines, not only because they are truly isogenic
but also because the cancer-derived cells are likely to contain a
number of other accumulated mutations and abnormalities that
could influence response to anticancer agents. It is unlikely that
the hypersensitivity seen in the Pms27/7/p537/7 cells was due
to the experimental set-up rather than being caused by the lack
of Pms2 function, because the increased sensitivity was also
observed, though to a lesser extent, in the clonogenic survival assay
and in the trypan blue exclusion assay. This observation indicates
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that the increased sensitivity to the platinum compounds, the
topoisomerase II poisons and the taxanes arises through enhanced
cell killing rather than only through decreased proliferation ability.
The increased cell killing by cisplatin in cells lacking Pms2 is paral-
leled by increased apoptosis.
The mechanism by which the MMR proteins may influence
damage response is not yet fully understood. One hypothesis
proposes that the MMR proteins recognise base damage and
initiate a cycle of futile repair, leading to gaps and breaks that
may ultimately signal apoptosis (Vaisman et al, 1998). It is also
possible that the recognition of damage by the MMR proteins
directly initiate a signal transduction pathway (Fink et al,
1998). Direct evidence supporting the latter hypothesis includes
a requirement for MLH1 function in cisplatin induction of c-
abl kinase activity (Nehme´ et al, 1997) and of p73 accumulation
(Gong et al, 1999).
An increased cytotoxic effect due to loss of Pms2 was observed
in p53-deficient cells to a panel of drugs that have different
modes of action and introducing different types of damage. The
molecular basis for the putative protective role of MMR in the
p53-independent response to platinum compounds, topoisomerase
II poisons and to taxanes is not yet clear. Loss of either Pms2 or
MLH1 (Vikhanskaya et al, 1999; Lin et al, 2001) results in p53-
deficient cells in hypersensitivity to cisplatin, whereas loss of
MLH1 or PMS2 results in p53-proficent cells in resistance to
cisplatin (Aebi et al, 1996; Fink et al, 1997). Likewise, cell kill
by topoisomerase II poisons, but not by taxanes, has been
reported to be affected by loss of MMR (Fedier et al, 2001; Lin
et al, 2001), indicating that MMR-dependent damage response
is, at least partially, modulated by p53. Indeed, cross talks between
MMR- and p53-dependent pathways have been reported (Duckett
et al, 1999; Wu et al, 1999). Cells defective in p53 function retain
the ability to mediate apoptosis by a p73-dependent pathway
(Gong et al, 1999), which may be modulated by certain MMR
proteins. It is possible that PMS2 and MLH1 protect cells from
excessive cell death by counteracting p73-mediated apoptosis in
a MMR-dependent manner upon DNA damage introduced by
cisplatin or topoisomerase II poisons. In a p53-independent path-
way PMS2 may, as in the case of cisplatin, decrease adduct
tolerance and damage accumulation on this basis. Oxaliplatin
and cisplatin produce different types of DNA damage and thus
have been shown to display a differential response in MMR-defi-
cient cells proficient for p53 (Fink et al, 1996). Our data thus
suggest a role for PMS2 in a DNA damage response pathway in
addition to that in MMR. However, the possibility can not be
excluded that p53 modulates oxaliplatin damage differently from
that of cisplatin damage. Likewise, PMS2 may modulate the effi-
cacy of the repair machinery to process stalled replication forks
arisen by blocked DNA-topoisomerase intermediates and gaps
introduced by the chain-terminating antimetabolite gemcitabine.
Additional loss of PMS2 thus abolishes the damage removal activ-
ity, giving rise to excessive DNA damage and cytotoxicity. The
finding that MMR-deficiency does not alter 5-fluorouracil cyto-
toxicity in a p53-deficient setting may be of clinical interest for
the treatment of colorectal cancer, despite the previously reported
in vitro association of MMR with resistance to 5-fluorouracil in
p53-proficient cells (Carethers et al, 1999).
p53 either mediates growth arrest, both in G1 or G2 phases of
the cell cycle, or directs cells to apoptosis. These two cellular deci-
sions are distinctive end points of p53 induction, depending on the
cellular context and the type of DNA damage. The present study
demonstrates that both Pms2-proficient and -deficient cells retain
the ability to arrest at the G2/M upon cisplatin treatment and that
loss of Pms2 is not accompanied by substantial alterations in the
characteristic changes in cell cycle distribution. A similar result
has also been reported in p53-deficient cells after loss of Msh2
(Strathdee et al, 2001) or MLH1 (Lin et al, 2001). Therefore, it
seems unlikely that MMR is a major trigger for a G2/M arrest in
cells that lack functional p53.
The feature that p53 and MMR proteins modulate cellular
responses upon DNA damage and the availability of genetically
engineered human and murine cells present a potential means to
develop strategies to circumvent the reduced responsiveness by
re-sensitising or by hypersensitising p53-mutant tumours to thera-
peutic regimens. Candidate approaches include the restoration of
the wild-type p53 function, the activation of cytotoxic pathways
that operate independently of p53, or the concurrent disruption
of genes implicated in DNA damage response pathways (Mcgill
and Fisher, 1999).
Since both, MMR and p53 status affect the mechanism of cyto-
toxicity, the genotype-based predictions may require that the MMR
status as well as the p53 status of the tumour are taken into
account. In summary, the present data show that p53-deficient cells
are sensitised to the platinum compounds, the topoisomerase II
poisons and the taxanes by the concurrent loss of Pms2 function.
Although PMS2 mutations or mutations in both PMS2 and p53 are
not frequently found in human cancers and thus may be of minor
clinical importance, our study may nevertheless contribute to
fostering the concept that tumour-targeted functional inhibition
of PMS2 may be an adjunct to chemotherapy in the treatment
of tumours unresponsive to therapeutic regimens due to mutations
in the p53 gene.
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Background: Ataxia-telangiectasia is a pleiotropic autosomal recessive disorder caused by mutations in the
ATM gene. In addition to a profound cancer predisposition, another hallmark of ataxia-telangiectasia is radio-
sensitivity. Recently, p53-null mouse fibroblasts have been reported to be radiosensitised by the concurrent loss
of ATM.
Materials and methods: We compared the sensitivity of atm+/+/p53–/– and atm–/–/p53–/– mouse embryonic
fibroblasts to different classes of chemotherapeutic agents using the MTT assay, Trypan Blue exclusion and
fluorescence-activated cell sorting for cell cycle and apoptosis analyses.
Results: Loss of ATM function in p53-deficient cells resulted in a 2- to 4-fold increase in sensitivity to the
topoisomerase I poisons camptothecin and topotecan, to the topoisomerase II poisons doxorubicin, epirubicin
and etoposide, and to the antimetabolites 5-fluorouracil and gemcitabine, but not to the platinum compounds
cisplatin, carboplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, or to busulfan. Loss of ATM
function did not result in increased apoptosis, but resulted in increased Trypan Blue staining in response to
epirubicin, suggesting that processes other than apoptosis may mediate cytotoxicity. ATM deficiency did not
alter the extent of G1/S or G2/M cell cycle phase accumulation produced by epirubicin, suggesting that enhanced
sensitivity was not due to failure of checkpoint activation.
Conclusions: We provide further evidence that ATM is involved in regulating cellular defences against some
cytotoxic agents in the absence of p53. Tumour-targeted functional inhibition of ATM may be a valuable
strategy for increasing the efficacy of anticancer agents in the treatment of p53-mutant cancers.
Key words: antimetabolites, ATM, cancer, drug sensitivity, p53, topoisomerase poisons
Introduction
The p53 tumour suppressor gene is the most frequently mutated
gene in human cancers [1]. p53 is involved in regulating cell cycle
checkpoints, apoptosis and DNA repair in response to DNA
damage, and thus plays a pivotal role in maintaining the integrity
of the genome [2]. Lack of functional p53 is associated with
abrogation of cell cycle checkpoint control and of apoptosis
induction. This contributes to resistance to radiotherapy and to
certain chemotherapeutic agents in some tissues [3]. The failure of
p53-mutant tumours to respond to therapeutic regimens is of
increasing concern. Strategies that cause cells to override the
DNA damage checkpoints, to block protective pathways or to
trigger apoptosis via p53-independent pathways are predicted to
sensitise cells to killing by genotoxic agents.
ATM is mutated in patients with ataxia-telangiectasia, a pleio-
tropic autosomal recessive disorder characterised by progressive
neurodegeneration, premature senescence, immunodeficiency,
predisposition to cancer, chromosomal instability and hyper-
sensitivity to γ-irradiation [4, 5]. ATM is a PI-3-like protein kinase
operating upstream of p53 [6] and it has been shown to bind to
free DNA ends produced by DNA double-strand breaks that occur
during normal replication and recombination, or in response to
exogenous genotoxic stress [7]. It is known to interact with a
variety of other targets in addition to p53, including c-Abl,
BRCAl, CHK2, MDM2 and DNA-PK [8, 9]. ATM plays a key
role in sensing DNA damage and in propagating signals that
modulate protective cellular responses to genotoxic agents. It
serves a surveillance function that helps maintain genomic integ-
rity by promoting cell cycle arrest and damage repair, and possibly
by recruiting repair proteins to the site of damage to prevent
double-strand break repair from entering an error-prone pathway
[10]. Ataxia-telangiectasia cells display defective p53 induction,
abrogation of G1/S and G2/M cell cycle checkpoints, and hyper-
sensitivity to γ-irradiation [5], suggesting that ATM and p53
interact in a common pathway in response to this type of DNA
damage. However, some p53-null mouse tissues have been shown
to be rendered radiosensitive by the concurrent loss of the ATM
gene [11], suggesting the existence of an ATM effector pathway
that is activated in response to ionising radiation but which does
not depend on p53.
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Because a very large fraction of human cancers is functionally
p53 deficient, and hence may be resistant to chemotherapeutic
agents, a means of sensitising p53-deficient tumours assumes
great importance. Therefore, we were interested in determining
whether p53-deficient cells could be sensitised to a panel of clinic-
ally important chemotherapeutic agents by the additional loss
of ATM function. We report here that loss of ATM function in
p53-null mouse embryonic fibroblasts results in hypersensitivity
to a panel of chemotherapeutic agents, indicating that ATM plays
a role in protective responses to DNA damage independently of
p53. The increased drug sensitivity of ATM-deficient cells was
not accompanied by increased apoptosis or by further alteration of
cell cycle checkpoint activation. Our data support the concept that
tumour-targeted functional inhibition of ATM may be a valuable
approach to improving the effectiveness of chemotherapeutic
agents in the treatment of p53-mutant cancers.
Materials and methods
Cell lines and culture conditions
The atm+/+/p53–/– and atm–/–/p53–/– mouse embryonic fibroblasts were gener-
ously provided by Dr P. Leder. Mice were generated by crossing p53–/– mice
in a FVB background to atm–/– mice [12]. The cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 4 mM L-glutamine
(Life Technologies, Basel, Switzerland), 15% heat-inactivated fetal calf serum
(Oxoid, Basel, Switzerland) and penicillin/streptomycin (100 U/ml, 100 µg/ml;
Life Technologies) at 37°C in a humidified atmosphere containing 5% carbon
dioxide. The human breast adenocarcinoma cell line MCF-7 was obtained
from the American Type Culture Collection (ATCC HTB 22; Manassas, VA,
USA) and maintained in Opti-MEM (Life Technologies supplemented with
10% heat-inactivated fetal calf serum. All cell lines tested negative for con-
tamination with Mycoplasma spp.
Drugs
Camptothecin and busulfan were purchased from Sigma (Buchs, Switzerland).
The following drugs were generous gifts: epirubicin and doxorubicin (Pharmacia
& Upjohn, Dubendorf, Switzerland), topotecan (SmithKline Beecham, Thoris-
haus, Switzerland), docetaxel (Aventis, Zurich, Switzerland), oxaliplatin (Sanofi-
Synthelabo, Meyrin, Switzerland), etoposide, paclitaxel, cisplatin and carbo-
platin (Bristol-Myers Squibb, Baar, Switzerland), 5-fluorouracil (Roche, Reinach,
Switzerland) and gemcitabine (Eli Lilly, Vernier, Switzerland).
Immunoblot analysis
To provoke p53 induction, exponentially growing cells were exposed to
25 nM epirubicin for 24 h and then collected as described. Cells were washed
in cold phosphate-buffered saline (PBS) and lysed on ice in 150 mM NaCl
containing 5 mM EDTA, 1% Triton X-100, 10 mM Tris–HCl (pH 7.4), 5 mM
dithiothreitol (DTT), 100 µg/ml phenylmethylsulfonyl fluoride and 1 µg/ml
aprotinin, followed by centrifugation at 14 000 g for 20 min at 4°C. The protein
amount was determined using the Bio-Rad protein assay dye (Bio-Rad,
Glattbrugg, Switzerland). After centrifugation, 150 µg (for ATM) or 50 µg
(for p53) of protein was boiled in an equal volume of 100 mM Tris–HCl
(pH 6.8) containing 20% glycerol, 200 mM DTT, 4% sodium dodecylsulphate
(SDS) and 0.2% bromophenol blue. The proteins were separated using SDS–
PAGE on a 5% gel for ATM and on a 10% gel for p53 analysis, followed by
blotting onto a polyvinylidene difluoride membrane (Amersham Pharmacia
Biotech, Little Chalfont, UK). ATM protein was detected using a mouse
monoclonal antibody directed against amino acids 2577–3056 (ATM-2CI;
GeneTex, Inc., San Antonio, TX, USA), whereas p53 protein was detected
using the mouse monoclonal antibody pAb 240 (Santa Cruz Biotechnology
Inc., Basel, Switzerland). After washing the blots, horseradish peroxidase-
conjugated antimouse antibody (BD Biosciences, Allschwil, Switzerland) was
added and the complexes were visualised by enhanced chemiluminescence
(Amersham Pharmacia Biotech).
Growth inhibition assay
Epirubicin, doxorubicin, topotecan, cisplatin, carboplatin, oxaliplatin,
5-fluorouracil and gemcitabine were diluted in 0.9% NaCl immediately
before use. Stock solutions of etoposide, camptothecin, paclitaxel and busul-
fan were prepared in dimethyl sulphoxide (DMSO), whereas docetaxel was
dissolved in methanol. The final concentration of DMSO or methanol in
the cultures was <0.1% at all drug concentrations and in controls. Previous
experiments (data not shown) have established that neither 0.1% DMSO
nor 0.1% methanol affects the viability or growth of these cell lines. Growth
inhibition in response to drug treatment was determined by the MTT assay
[13]. Cells growing in the log phase were harvested by brief trypsinisation and
washed once with medium containing 15% fetal calf serum. MTT assays were
performed by seeding 500 (atm–/–/p53–/–) or 1000 (atm+/+/p53–/–) cells into
96-well plates 24 h before incubation without or with the drug for 5 days. A
volume of 20 µl MTT in PBS was added to a final concentration of 0.5 mg/ml,
followed by incubation at 37°C for 4 h, aspiration of the medium and addition
of DMSO 200 µl. Optical density was measured by the Emax microplate
reader E9336 (Molecular Devices, Clearwater, MN, USA) at 540 nm, setting
the value of the cell lines in medium to 1.0 (control) and the value of the no
cells blank to zero. Differences in drug sensitivity of the respective cell lines
were determined from at least four independent experiments and are reported
as the concentration required to suppress growth by 50% (IC50).
TUNEL apoptosis assay
Cells were grown to 70% confluence in 60 mm dishes in triplicate cultures and
then treated with 25 nM epirubicin. Adherent and floating cells were collected
at the time points indicated and washed in PBS. Cells were then fixed in 4%
paraformaldehyde on ice for 30 min, followed by dropwise addition of ice-
cold 70% ethanol. Samples were stored at 4°C until further use. Samples were
washed twice with PBS and resuspended in the TUNEL reaction mixture and
incubated at 37°C for 2 h, according to the manufacturer’s protocol (Roche
Molecular Biochemicals, Basel, Switzerland). Cells were analysed by flow
cytometry (EPICS ELITE; Beckmann-Coulter, Hialeah, FL, USA).
Trypan Blue exclusion assay
Cell viability after drug treatment was determined by means of the Trypan
Blue exclusion assay. Cells were grown to 60% confluence and incubated
without (controls) or with 25 nM epirubicin for 24, 48 or 72 h. At the indicated
time points, floating and adherent cells were collected. Cells were then
incubated with Trypan Blue solution (0.1% final concentration) for 1 min, and
the number of Trypan Blue-positive and -negative cells was determined using
a haematocytometer.
Cell cycle analysis
Cells were grown to 50% confluence in 60 mm dishes. Cells were then incu-
bated with or without (controls) epirubicin 10 nM. This dose inhibited growth
of ATM-deficient cells by at least 70% in the MTT assay. Before collection by
trypsinisation at the times indicated, cells were incubated with BrdU 10 µM
(Serva, Heidelberg, Germany) at 37°C for 8 h. Samples were washed in ice-
cold PBS, resuspended in PBS 100 µl, fixed by dropwise addition of ice-cold
70% ethanol and stored at 4°C until use. Then, ethanol was removed by
centrifugation (3000 g) and cells were resuspended and incubated in 2 N HCl/
0.5% Triton X-100 for 30 min at room temperature, followed by centrifugation
(3000 g) and resuspension in 0.1 M Na2B4O7 to neutralise the acid. After
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collection of the pellet by centrifugation, cells were resuspended and incu-
bated in PBS 500 µl /0.5% Tween-20/1% bovine serum albumin (BSA) and
further incubated with FITC-conjugated anti-BrdU antibody (5 µg/ml; BD
Biosciences) at room temperature for 30 min. Nuclei were then collected by
centrifugation (3000 g) and incubated in 1 ml of propidium iodide staining
solution (50 µg/ml propidium iodide and 100 U/ml RNase A in PBS) at room
temperature for 1 h, followed by washing once in PBS containing 0.5% BSA.
All light-sensitive steps were carried out in twilight. Samples were analysed
for BrdU incorporation and DNA content by flow cytometry (EPICS ELITE;
Beckmann-Coulter), and the percentage of cells in each phase was determined
using the MultiCycle for Windows Software (Phoenix Flow Systems, San
Diego, CA, USA).
Statistical analysis
Mean ± SD are indicated for all data sets. The two-sided paired t-test was
performed to compare the effects of loss of ATM function on drug sensitivity.
P <0.05 was considered to be statistically significant.
Results
Loss of ATM and increased sensitivity to topoisomerase I 
and II poisons and to antimetabolites
Loss of the ATM gene has previously been reported to render
p53-null mouse tissues more sensitive to γ-irradiation [11]. Using
a pair of mouse knockout cell lines, we determined the effect of
loss of ATM function in a p53-null background on sensitivity to
a panel of anticancer agents. atm+/+/p53–/– cells are replete with
respect to ATM but lack expression of p53, whereas atm–/–/
p53–/– cells express neither ATM nor p53 protein (Figure 1).
Figure 2 shows the extent of growth inhibition for both cell lines
as a function of drug concentration in response to continuous
exposure to the topoisomerase II poisons epirubicin and etopo-
side, to the topoisomerase I poisons camptothecin and topotecan,
and to the antimetabolites 5-fluorouracil and gemcitabine. The
IC50 values for all the drugs tested are summarised in Table 1.
The atm–/–/p53–/– cell line was 3.2-fold (P = 0.0004, n = 5) more
sensitive to epirubicin and 3.1-fold (P = 0.003, n = 5) more sensi-
tive to etoposide than the atm+/+/p53–/– cell line. Likewise, a
3-fold (P = 0.0001, n = 5) greater sensitivity was also found for
doxorubicin. In addition, atm–/–/p53–/– cells displayed a 3.6-fold
increased sensitivity to camptothecin (P = 0.0001, n = 4) and a
2.7-fold increased sensitivity to topotecan (P = 0.01, n = 4) as
compared with the ATM-proficient cells. They were also 2-fold
hypersensitive to 5-fluorouracil (P = 0.0001, n = 5) and 2.1-fold
hypersensitive to gemcitabine (P = 0.003, n = 5) as compared
with atm+/+/p53–/– cells. Thus, the additional loss of the ATM gene
in a p53-deficient genetic background resulted in a 2- to 4-fold
increased sensitivity to the topoisomerase I and II poisons, and to
some types of antimetabolites.
Loss of ATM and unaltered sensitivity to platinum 
compounds, taxanes or the alkylating agent busulfan
Figure 3 shows the extent of growth inhibition for atm+/+/p53–/–
and atm–/–/p53–/– cells in response to a continuous exposure to
the platinum compounds cisplatin, carboplatin and oxaliplatin, to
the alkylating agent busulfan, and to the microtubule poisons
docetaxel and paclitaxel. The IC50 values for these drugs are
reported in Table 1. There was no difference in sensitivity
between the atm+/+/p53–/– and atm–/–/p53–/– cells with respect to
treatment with cisplatin (P = 0.38, n = 5), carboplatin (P = 0.36,
n = 5), oxaliplatin     (P = 0.15, n = 5), docetaxel (P = 0.81, n = 4),
paclitaxel (P = 0.51, n = 4) or busulfan (P = 0.14, n = 5). Thus, loss
of the ATM function in p53-null cells does not alter the sensitivity
to platinum compounds, to taxanes, or to the alkylating agent
busulfan.
ATM deficiency and increased apoptosis
The TUNEL apoptosis assay was performed to determine whether
the increased sensitivity to epirubicin due to loss of ATM function
was accompanied by increased apoptosis. Treatment with 25 nM
epirubicin, which inhibited growth of ATM-deficient cells by
more than 85%, produced 3- to 4-fold more apoptotic atm+/+/
p53–/– cells than atm–/–/p53–/–cells (Figure 4). The respective
values were 9 ± 6% versus 2 ± 1% at 34 h after epirubicin treat-
ment, and 13 ± 3% versus 4 ± 1% at 57 h after treatment. These
results indicate that the hypersensitivity to the cytotoxic effect of
epirubicin in ATM-deficient cells is not associated with increased
apoptosis.
Loss of ATM and overall cell viability in response to the 
topoisomerase II poison epirubicin
The Trypan Blue exclusion assay was performed to clarify the
apparently discrepant results observed with epirubicin in the
different assay systems. The data indicate that loss of ATM func-
tion was associated with a 2- to 3-fold increase in the number of
Trypan Blue-positive cells following exposure to 25 nM epiru-
bicin (Figure 5). The changes in the proportion of Trypan Blue
excluding cells with the time after drug treatment were also
monitored. The decrease in viability was faster in the ATM-
deficient cells than in the ATM-proficient cells (55 ± 8% versus
20 ± 8% at 48 h, 71 ± 11% versus 42 ± 12% at 72 h). This parallels
the data obtained in the MTT assay. Thus, both the growth rate
inhibition assay and the Trypan Blue assay indicate that loss of
Figure 1. Immunoblot analysis of the expression of ATM and/or p53 
protein in atm+/+/p53–/– and atm–/–/p53–/– cells. The human breast cancer cell 
line MCF-7 was used as a positive control. atm+/+/p53–/– cells lack the 
expression of p53, whereas atm–/–/p53–/– cells express neither ATM nor p53.
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Figure 2. Sensitivity to a continuous exposure to epirubicin, etoposide, camptothecin, topotecan, 5-fluorouracil and gemcitabine in atm+/+/p53–/– (filled 
squares) and atm–/–/p53–/– (open squares) cells as determined by the MTT assay. Each point represents the mean of at least four independent experiments. 
Bars = SD.
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ATM function reduces the threshold for cell kill by a process that
does not depend on apoptosis.
Loss of ATM and cell cycle phase distribution after 
treatment with the topoisomerase II poison epirubicin
To determine whether the differential sensitivity of ATM-
proficient and -deficient cells to epirubicin was due to alteration
in the ability to trigger G1/S phase arrest, the fraction of cells in
S phase was quantified as a function of drug exposure. Table 2
shows that 10 nM epirubicin reduced the fraction of ATM-
proficient and -deficient cells in S phase after 24 h to about the
same extent.
An alternative hypothesis is that the differential sensitivity to
epirubicin is due to altered ability to activate the G2/M checkpoint.
Cells were exposed to 10 nM epirubicin, a concentration that
inhibited the growth of ATM-deficient cells in the MTT assay by
at least 70%, and the fraction of cells in G2/M was determined at
various time points. The data presented in Table 3 demonstrate
that epirubicin produced a transient 1.3-fold accumulation of
ATM-deficient cells in G2/M at 24 h, largely at the expense of
cells in G1. Thus, ATM-deficient p53-null cells seemed to retain,
at least partially, the ability to arrest in G2/M in response to
epirubicin. A comparable analysis of the response of ATM-
proficient cells to epirubicin could not be interpreted due to the
rapid formation of hyperploid cells.
Taken together, the cell cycle data suggest that ATM does not
play a central role in the ability of epirubicin to trigger either the
Gl/S or G2/M checkpoint, and that the differential sensitivity of
ATM-proficient and -deficient p53-null cells cannot be accounted
for by loss of either of these cell cycle control elements.
Discussion
We report here that p53-null cells are sensitised by the loss of the
ATM gene to topoisomerase I and II poisons and several types of
antimetabolites, but not to the major platinum compounds, the
major taxanes and one alkylating agent. The data permit several
conclusions to be drawn. First, they extend the previous
observation that p53-deficient mouse tissues are rendered more
sensitive to γ-irradiation by the concurrent loss of ATM [11] by
identifying classes of anticancer agents to which these cells
are also hypersensitive. Secondly, they support the existence of
an ATM-dependent, p53-independent DNA damage-induced
effector pathway and the role of ATM as a sensor for specific
types of DNA damage [5, 14]. Thirdly, the effector pathway
activated by ATM in the absence of p53 must involve some as yet
unravelled cellular defence mechanism(s), because the increased
chemosensitivity of ATM-deficient cells was not accompanied by
increased apoptosis or by altered activation of either the G1/S or
G2/M checkpoints.
ATM may function as a sensor of DNA double-strand breaks
arising from γ-irradiation [11] and, as reported here, from some
types of anticancer agents including topoisomerase poisons or
antimetabolites. However, it does not sense lesions produced by
microtubule poisons or platinum compounds. This is perhaps not
surprising for docetaxel and paclitaxel, since they are not known
to interfere with DNA. Perhaps, as for UV radiation-introduced
DNA damage [14], ATR, another member of the PIK family
[9, 15], is responsible for sensing damage produced by platinum
drugs. ATR and ATM are partially redundant, and they act in
parallel but overlapping DNA damage signalling pathways, but
respond primarily to different kinds of lesions [7, 15].
ATM regulates cell cycle checkpoint activation upon DNA
damage causing cells to arrest in G1/S and/or G2/M, ensuring that
cells delay entry into mitosis and putatively permitting time for
damage repair prior to the onset of mitosis [16]. Although stress
may cause overriding of the G1/S and the G2/M arrests in p53-
mutant cells [2], damage-mediated activation of ATM may stop
cells at the G2/M checkpoint in these cells [16]. However, loss of
ATM does not substantially affect either G1/S or G2/M checkpoint
activation in p53-deficient cells after γ-irradiation [17]. Our data
show that the increased sensitivity of these cells to epirubicin
cannot be explained by the lack of ATM-mediated cell cycle
checkpoint control. Indeed, ATM, unlike ATR, does not seem to
modulate the length and magnitude of the G2 arrest induction
[18, 19].
The primary mechanism by which ATM exerts its protective
effect may be through modulating damage repair and decreasing
the threshold for cell kill [10]. ATM immunoprecipitates with
DNA damage repair proteins including MLH1, MSH2, MSH6
and BRCA1, and may facilitate recruitment of repair proteins
to the site of the lesion [20]. When such damage remains unre-
paired as the cell enters mitosis, the increased rate of chromosome
breaks and aberrant chromosome segregation results in increased
cell killing [11]. Our results indicate that the increased chemo-
sensitivity of the ATM-deficient cells may be a result of processes
other than apoptosis.
Table 1. IC50 for ATM-proficient or -deficient p53-null cells determined by 
MTT assaya
aData are expressed as the mean ± SD of at least four independent 
experiments.
bS represents the sensitisation factor.
cP values for statistical significance were determined by the two-sided 
paired t-test.
Drug atm+/+/p53–/– atm–/–/p53–/– Sb Pc
Epirubicin (nM) 12.0 ± 2.0 3.7 ± 0.6 3.2 0.0004
Doxorubicin (nM) 34.4 ± 5.3 11.6 ± 4.8 3.0 0.0001
Etoposide (nM) 16.2 ± 5.3 5.2 ± 1.5 3.1 0.003
Camptothecin (nM) 26.4 ± 3.2 7.4 ± 1.1 3.6 0.0001
Topotecan (nM) 91.8 ± 24.6 34.6 ± 8.8 2.7 0.01
5-Fluorouracil (µM) 3.1 ± 0.4 1.6 ± 0.2 2.0 0.0001
Gemcitabine (nM) 19.1 ± 5.1 8.9 ± 1.6 2.1 0.003
Cisplatin (µM) 0.37 ± 0.14 0.44 ± 0.14 0.9 0.38
Carboplatin (µM) 5.4 ± 1.5 6.1 ± 1.3 0.9 0.36
Oxaliplatin (µM) 2.9 ± 0.3 2.4 ± 0.6 1.2 0.15
Busulfan (mM) 0.20 ± 0.07 0.14 ± 0.03 1.4 0.14
Docetaxel (nM) 5.4 ± 1.5 5.0 ± 2.4 1.1 0.81
Paclitaxel (nM) 35.6 ± 5.5 33.0 ± 6.3 1.1 0.51
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Figure 3. Growth inhibition in response to a continuous exposure to cisplatin, carboplatin, oxaliplatin, busulfan, docetaxel and paclitaxel in atm+/+/p53–/– 
(filled squares) and atm–/–/p53–/– (open squares) cell lines as determined by the MTT assay. Each point represents the mean of at least four independent 
experiments. Bars = SD.
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This study supports the concept that tumour-targeted functional
inhibition of ATM increases the efficacy of some anticancer
agents in the treatment of p53-deficient cancers, which comprise a
large proportion of human tumours [1].
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Abstract. Histone deacetylase (HDAC) inhibitors such as
suberoylanilide hydroxamic acid (SAHA, Vorinostat), valproic
acid (VPA), and FK228 are members of a relatively novel
class of small molecular weight chemicals that have high anti-
neoplastic activity. They cause growth inhibition and apoptosis
specifically in tumor cells, and they act also as chemo- and
radio-sensitizers. In the present study, the potential of SAHA
and VPA to induce resistance was studied. To that aim HDAC
inhibitor-resistant sublines were generated by stepwise
exposure of colon tumor cells to increasing concentrations
of these compounds. Clonogenic data demonstrated that the
SAHA- and VPA-induced sublines were 2-fold resistant to
these compounds. This resistance was non-reversible, as it
was maintained even when the sublines were cultured in the
absence of SAHA or VPA. The SAHA- and VPA-induced
resistant sublines were also stably cross-resistant to VPA
and SAHA, respectively, but retained sensitivity against non-
HDAC inhibitor-type anticancer agents. The SAHA-induced
resistance correlated with loss of the G2/M checkpoint but it
was not accompanied by reduced induction of the endogenous
cell cycle inhibitors p21 and p27. Furthermore, SAHA-induced
resistance was not due to reduced apoptosis, and it was neither
dependent on MDR expression nor was it due to increased
expression of HDAC1 and HDAC3. Taken together, these
data demonstrate the potential of SAHA and VPA to induce
resistance. This resistance was not dependent on MDR
expression, did not involve MMR, and seemed to underlie a
mechanism that differs from that underlying the previously
observed FK228-induced resistance. The finding that SAHA
and VPA induce only modest resistance despite continuous
treatment and that the resistance is MDR-independent suggests
a preference for these two drugs over FK228 for use in
combination treatment with classic anticancer agents.
Introduction
Enzymes modifying the activity of histones, such as histone
acetyltransferases (HATs) and histone deacetylases (HDACs),
are crucial to proliferation, apoptosis, development, angio-
genesis, and carcinogenesis. The balance between these
activities regulates the expression of genes controlling these
processes, mainly by regulating the accessibility of DNA-
interacting proteins for the DNA. HDAC-mediated silencing of
tumor suppressor genes plays a role in cancer pathophysiology.
HDACs are subdivided in four classes: class I (HDAC1, -2, -3,
-8), class II (HDAC4, -5, -6, -7, -9, -10), class III (also
referred to as sirtuins: SIRT1 through SIRT7), and class IV
(HDAC11) (1-3).
Inhibitors of HDACs counteract the removal of acetyl-
groups from histones and render the DNA available for DNA-
interacting proteins. HDAC inhibitors have strong anticancer
properties and many of them have moved forward into clinical
trials, and Vorinostat (suberoylanilide hydroxamic, SAHA)
has even been granted market approval for the indication of
cutaneous T-cell lymphoma (4-7). HDAC inhibitors induce
cell cycle checkpoint activation and apoptosis specifically in
tumor cells (8-12). They also radio- and chemo-sensitize
tumor cells (13,14). HDAC inhibitors have also been linked
to some characteristics of DNA repair (15,16), suggesting
that HDAC inhibitors can induce abnormal DNA structures
that may be recognized by DNA repair proteins (17).
Recent studies have shown that the powerful HDAC
inhibitor FK228 (depsipeptide) can induce reversible FK228
resistance in tumor cells by reversible induction of MDR1
(18,19), a multidrug resistance transporter that functions by
extrusion of cytotoxic drugs from the cell and by mediating
sequestration of the drugs into intracellular compartments,
both leading to a reduction in effective intracellular drug
concentrations (20). Expanding on this issue, we investigated
whether the HDAC inhibitors SAHA and valproic acid (VPA),
which are structurally unrelated to FK228, are potential
inducers of HDAC inhibitor resistance in tumor cells and
whether HDAC inhibitor-induced resistance is associated
INTERNATIONAL JOURNAL OF ONCOLOGY  31:  633-641,  2007 633
The histone deacetylase inhibitors suberoylanilide hydroxamic
(Vorinostat) and valproic acid induce irreversible and 
MDR1-independent resistance in human colon cancer cells
ANDRE FEDIER1,  KONSTANTIN J. DEDES1,  PATRICK IMESCH1,  ANDRE O. VON BUEREN2 and DANIEL FINK1
1Department of Gynecology, University Hospital Zurich; 2Division of Oncology, 
University Children's Hospital Zurich, Zurich, Switzerland
Received February 7, 2007;  Accepted March 27, 2007
_________________________________________
Correspondence to: Dr André Fedier, Department of Gynecology,
University Hospital of Zurich, Frauenklinikstrasse 10, CH-8091
Zurich, Switzerland
E-mail: andre.fedier@usz.ch
Key words: cell cycle, apoptosis, drug resistance, histone deacteylase
inhibitors, multidrug resistance, p21 and p27, suberoylanilide
hydroxamic acid
633-641  24/7/07  11:02  Page 633
with cross-resistance to non-HDAC inhibitor-type anticancer
agents, inducible MDR1 expression, reduced expression of
the HDAC-responsive gene p21, altered expression and/or
acetylation status of HDACs, and impaired cell cycle check-
point and apoptosis activation. To this aim and to determine
a possible involvement of DNA mismatch repair (MMR),
respective sublines of a pair of human adenocarcinoma cell
lines either expressing the MMR protein MLH1 (MLH1-
proficient HCT116ch3) or lacking MLH1 expression (MLH1-
deficient HCT116ch2) were generated by stepwise exposure
of these cell lines to increasing concentrations of HDAC
inhibitors.
Our results identify SAHA and VPA as potential inducers
of a non-reversible and MDR1-independent HDAC inhibitor
resistance phenotype. This resistance seems to be different to
that observed with FK228 and not dependent on the MMR-
status of the tumor cells.
Materials and methods
Drugs and chemicals. Suberoylanilide hydroxamic acid
(SAHA; Alexis Biochemicals, Lausen, Switzerland) and
valproic acid (VPA; Sigma, Buchs, Switzerland) were
purchased, as were cisplatin, docetaxel, and 6-thioguanine
(Sigma). Temozolomide was a generous gift (Schering-Plough,
Kenilworth, NJ). Stock solutions were prepared in DMSO
(SAHA, temozolomide), in ethanol (docetaxel), or in H2O
(cisplatin, 6-thioguanine, VPA). All stock solutions were stored
at -20˚C.
Cell culture and generation of HDAC inhibitor-resistant
sublines. A pair of an MLH1-deficient human colorectal adeno-
carcinoma cell line (designated HCT116ch2, complemented
with chromosome 2) and its MLH1-proficient counterpart
(designated HCT116ch3, complemented with chromosome 3),
which were derived from the MLH1-deficient parental human
colorectal adenocarcinoma cell line HCT116 (American Type
Culture Collection; ATCC CCL 247), were used. The charac-
teristics of the cell lines (e.g. chromosome complementation)
and the culturing conditions have been described previously
(21-23). A HeLa cell line (provided by Dr G. Marra, Institute of
Molecular Cancer Research, University of Zurich, Switzerland)
was also used. When seeded sparsely on tissue culture plates,
all the cell lines and sublines formed well-defined individual
colonies.
Similar to the method described previously (18), the HDAC
inhibitor-resistant cell sublines, hereafter designated as
HCT116ch3/SAHA, HCT116ch2/SAHA, HCT116ch3/VPA,
or HCT116ch2/VPA, respectively, were generated by step-
wise exposures of the MLH1-proficient HCT116ch3 cell line
and the MLH1-deficient HCT116ch2 cell line to increasing
concentrations of either SAHA or VPA, starting with 1 μM
for SAHA or 2.5 mM for VPA. A similar protocol was used
to generate the HeLa/SAHA subline. The principle of selection
was the clonal growth in the presence of increasing concen-
trations of the HDAC inhibitor, based on the idea that cells
are altered by chronic HDAC inhibitor exposure in that they
acquire new features in an irreversible fashion. Basically,
cells (100,000) were plated in cell culture flasks and treated
with SAHA or VPA 24 h after plating. After another 48 h,
the HDAC inhibitor-containing medium was exchanged for
inhibitor-free medium, followed by incubation for another 6
days to allow recovery of the surviving cells. These were then
harvested by trypsinization, transferred into new flasks, and
expanded to confluence. One fraction was stored at -80˚C
(for protein analysis), the other (100,000 cells) was re-seeded
in culture flasks and was subjected to treatment with SAHA or
VPA 24 h later, to medium exchange, recovery and harvesting
as described. This protocol was repeated (10 times for SAHA,
8 timed for VPA), and for each cycle, the concentrations of
SAHA or VPA were incremented, resulting in a 6-fold total
increment for SAHA (6 μM) and 60-fold for VPA (150 μM).
The growth rates of the cell lines and the sublines were
calculated from the doubling times from one passage to the
subsequent and averaged for a period of two months. MLH1
gene expression in the cell lines and sublines was determined
by immunoblotting.
Drug sensitivity assay. In a typical clonogenic assay, 400
cells in medium were plated onto 60-mm cell culture dishes,
followed by drug addition after 24 h. For a 24-h treatment
the medium was replaced by drug-free medium 24 h after
drug addition; for a continuous treatment (8 days) the drug-
containing medium was maintained. Cells were incubated
for 7 days to allow colony formation, fixed with 25% acetic
acid in ethanol and stained with Giemsa. Colonies of at least
50 cells were scored. Each experiment was performed at
least three times using triplicate cultures. The relative colony
formation (% clonogenic survival) was plotted against the
drug concentrations, and the IC50 concentrations were calc-
ulated by linear extrapolation.
Apoptosis and cell cycle analyses by flow cytometry. Analyses
of apoptosis (TUNEL DNA fragmentation) and cell cycle
were performed by flow cytometry on a FACSCalibur flow
cytometer (BD Biosciences; Allschwil, Switzerland) with
CELLQuest software (BD Biosciences). Data analyses for
apoptosis and cell cycle distribution were performed on linear
PI histograms using the mathematical software ModFit LT 2.0
(Verity Software House; Topsham, ME, USA). For sample
preparation, cells were grown to 70% confluence in 60-mm
dishes and treated with the concentration of SAHA which
reduced clonogenic survival by at least 95%. At the times
indicated, adherent and floating cells were collected and
prepared for apoptosis and cell cycle analysis as described
previously (23).
Immunoblot analysis. After cells had grown to 70% confluence
in 60-mm dishes, they were treated with SAHA or TSA and
collected 3, 7, or 14 h later, washed in PBS, and prepared for
immunoblot analysis performed following standard protocols
for PAGE gel electrophoresis. Protein (20 μg) was separated
using 10% SDS-PAGE, followed by blotting onto a poly-
vinylidene difluoride membrane (Amersham Biosciences,
Otelfingen, Switzerland). Expression of MLH1 protein was
detected by the mouse antibody (550838; BD Biosciences
Pharmingen, Basel, Switzerland) and the anti-mouse secondary
horseradish peroxidase-conjugated antibody (M15345;
Transduction Laboratories, Lexington, KY). p21 and p27
proteins were detected by the rabbit antibody (05-345; Upstate,
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Lucerna Chem AG, Lucerne, Switzerland) and the rabbit
antibody (2552; Cell Signaling, BioConcept, Allschwil,
Switzerland), respectively. p53 and MDR1 were detected
by the respective rabbit antibodies (sc-6243, sc-13131;
Santa Cruz Biotechnology Inc., LabForce AG, Nunningen,
Switzerland). HDAC1, -3, -4, -5, -6, and -7 were detected by
rabbit antibodies (Kit 9928; Cell Signaling), acetyl-histone
H3 (Lys9) and acetyl-histone H4 (Lys8) by the respective
rabbit antibodies (6971, 2594; Cell Signaling). The anti-rabbit
secondary horseradish peroxidase-conjugated antibody (7074;
Cell Signaling) was used. As a sample loading control, the
mouse antibody against ß-actin (A5441; Sigma) was used. All
the complexes were visualized by enhanced chemiluminescence
(Amersham Biosciences). Quantitative analysis of the
complexes (intensity on the autoradiograph) was performed
by densitometry (normalized against ß-actin) using the Scion
Image 4.01 Win software (Scion Corporation, Frederick, MD).
Statistical analysis. The mean ± SD values were calculated
for all data sets. A p value <0.05 was considered statistically
significant (paired, two-tailed Student's t test).
Results
Resistance induction by SAHA and VPA. Clonogenic data
revealed that the MLH1-deficient cell line (HCT116ch2) was
as sensitive as the MLH1-proficient cell line (HCT116ch3) to
a continuous (8 days) treatment with SAHA or VPA (Fig. 1A
and B). For the generation of the SAHA- and VPA-induced
sublines, the respective IC90 concentrations were determined,
being 1 μM for SAHA and 2.5 μM for VPA. Expression of
MLH1 protein was present in both sublines derived from the
HCT116ch3 cell line and was absent in those derived from
the HCT116ch2 cell line (Fig. 1C). The growth rates of the
HDAC inhibitor-induced sublines were similar to those of
the non-induced cell lines (Table I).
It was determined whether these HDAC inhibitor-induced
sublines are on the one hand resistant to the agent by which
they were induced and on the other cross-resistant to VPA, a
carboyxylate HDAC inhibitor which is structurally different
from SAHA, a member of the hydroxamic acids class of
HDAC inhibitors. The results (Fig. 2; Table II) showed that
both the MLH1-proficient and the MLH1-deficient SAHA-
induced sublines were 2-fold (p<0.01) resistant to SAHA
(Fig. 2A) and also 2-fold (p<0.01) cross-resistant to VPA
(Fig. 2B). Likewise, VPA treatment also induced a 2-fold
(p<0.01) resistance to VPA (Fig. 2C) as well as a 2-fold
(p<0.01) cross-resistance to SAHA (Fig. 2D), irrespective of
the MLH1 status of the cells. 
To consider a possible contribution of the complemented
chromosomes, resistance induction by SAHA was also
investigated for the parental HCT116 cell line. The results
showed that 8 cycles of SAHA treatment also induced a 2-fold
(p<0.01) resistance with this cell line. The respective IC50
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Figure 1. Clonogenic survival of MLH1-proficient HCT116ch3 (ƒ) and
MLH1-deficient HCT116ch2 (∫) human colorectal adenocarcinoma cells
after an 8-day treatment with the HDAC inhibitors SAHA (A) and VPA (B).
Each point is the mean ± SD of three independent experiments performed
in triplicate cultures. (C) The presence or absence of MLH1 expression in
the HCT116ch3 (ch3) or HCT116ch2 (ch2) cells, respectively, and in the
corresponding HDAC inhibitor-induced sublines (ch3/SAHA, ch3/VPA,
ch2/SAHA, ch2/VPA). ß-actin is the sample loading control.
Table I. Comparison of the cell doubling time.
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell lines Doubling time (h)a
–––––––––––––––––––––––––––––––––––––––––––––––––
HCT116+ch3 21.4±1.1
HCT116+ch3/SAHA 23.4±0.5
HCT116+ch3/VPA 23.7±0.5
HCT116+ch2 21.6±0.9
HCT116+ch2/SAHA 22.4±1.3
HCT116+ch2/VPA 23.8±1.1
–––––––––––––––––––––––––––––––––––––––––––––––––
aThe doubling times of the cell lines and the respective sublines
were calculated from one passage to the subsequent and averaged
for a period of two months. The values represent the mean ± SD of
5 independent data sets.
–––––––––––––––––––––––––––––––––––––––––––––––––
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values were 0.6±0.1 μM (HCT116) vs. 1.3±0.3 μM (HCT116/
SAHA). Notably, SAHA (80-fold increment, 7 cycles) failed
to induce resistance in HeLa cells. The respective IC50 values
were similar: 1.1±0.1 μM (HeLa) vs. 1.3±0.1 μM (HeLa/
SAHA).
It is noteworthy that all the HDAC inhibitor-induced sub-
lines maintained resistance for at least 6 months (>30 passages,
maximum period of time tested) even when cultured in HDAC
inhibitor-free medium. In addition, the SAHA-resistant sublines
were not cross-resistant to non-HDAC inhibitor-type anti-
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Figure 2. Clonogenic survival after an 8-day treatment with HDAC inhibitors for the MLH1-proficient HCT116ch3 (ƒ) and MLH1-deficient HCT116ch2 (∫)
cell lines (straight lines) and the respective SAHA-induced (A, B) or VPA-induced (C, D) sublines (dashed lines). (A, C) Resistance to the HDAC inhibitors
themselves; (B, D) cross-resistance of SAHA-induced sublines to VPA. Shown is also the cross-resistance of SAHA-induced sublines to the non-HDAC
inhibitor-type antitumor agents cisplatin (E), docetaxel (F), 6-thioguanine (G), and temozolomide (H). Each point is the mean ± SD of 4 independent
experiments performed in triplicate cultures.
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cancer agents such as cisplatin, docetaxel, 6-thioguanine, and
temozolomide, regardless of the MLH1 status of the cells
(Fig. 2E-H).
SAHA-induced sublines and G2/M checkpoint activation. It was
determined whether loss of cell cycle checkpoint activation
accounted for the observed SAHA-induced resistance. Flow
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Figure 3. G2/M cell cycle checkpoint induction in the SAHA-induced sublines and the corresponding non-induced cell lines in response to a 24-h exposure to 5 μM
SAHA. (A) Representative cell cycle phase distribution profiles of the DNA content obtained by flow cytometry for the MLH1-proficient (HCTch3) and the
MLH1-deficient (HCTch2) HCT116 cell lines and the respective sublines induced by SAHA (HCTch3/SAHA, HCTch2/SAHA). X-axis (channels): position of
cells accumulated in G1, S, or G2/M. Y-axis; number of events per channel. (B) Quantitative presentation of primary flow cytometry data captured 24 h post-
treatment of the cells with 5 μM SAHA. The changes in the proportion of cells accumulated at the G2/M (black) transition, in the S phase (white), and at the
G1/S transition (grey) are presented. Each point is the mean ± SD of 3 independent experiments. *p<0.05.
Table II. IC50 values for the MLH1-proficient HCT116ch3 cell line and the MLH1-deficient HCT116ch2 cell line and the
respective sublines derived from stepwise exposure to SAHA.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Inhibitor HCT116ch3 HCT116ch3/SAHA Fold changea HCT116ch2 HCT116ch2/SAHA Fold changea
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SAHA (μM) 1.7±0.1 3.9±0.2 2.3b 1.6±0.1 3.2±0.6 2.0b
VPA (mM) 2.1±0.3 4.7±1.3 2.2b 2.1±0.2 4.2±0.5 2.0b
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HCT116ch3 HCT116ch3/VPA Fold changea HCT116ch2 HCT116ch2/VPA Fold changea
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
VPA (mM) 1.4±0.2 2.6±0.3 1.9b 1.4±0.2 2.6±0.3 1.9b
SAHA (μM) 0.7±0.1 1.3±0.3 1.9b 0.7±0.1 1.4±0.3 2.0b
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aFold change is referred to as resistance or cross-resistance and is defined as the ratio of the IC50 values for the sublines and those for the
non-induced cell lines. bp<0.01.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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cytometry data analysis (Fig. 3) demonstrated that 5 μM SAHA
(reduced clonogenic survival by >95%) produced an arrest
at the G2/M transition of the cell cycle in both the MLH1-
proficient HCT116ch3 and the MLH1-deficient HCT116ch2
cell lines. This, however, was not observed for the respective
SAHA-induced sublines, HCT116ch3/SAHA and HCT116ch2/
SAHA. This demonstrated that the ability to induce the G2/M
checkpoint was substantially (2-fold, p<0.05) reduced in the
SAHA-induced sublines as compared to the non-induced cell
lines, indicating that loss of this checkpoint contributes to the
SAHA-induced resistance observed for these sublines.
SAHA-induced resistance and regulation of p21 or p27. It
was determined whether the SAHA-induced resistance was
accompanied by reduced induction of p21 and/or p27, two
endogenous cell cycle inhibitors induced by HDAC inhibitors
(24-26). Immunoblot data showed that SAHA strongly induced
p21 and p27 expression in all samples, i.e. in both sublines
(MLH1-proficient and MLH1-deficient) and in the respective
sublines (Fig. 4A), demonstrating that SAHA-induced
resistance and loss of the G2/M checkpoint were not due to
loss of p21 and p27 induction in the resistant sublines.
SAHA-induced resistance and apoptosis. DNA fragmentation
data (Fig. 4B) showed that susceptibility to SAHA-imposed
apoptosis was nearly the same for the SAHA-induced (resistant)
sublines and for the non-induced (sensitive) cell lines, regardless
of the presence or absence of MLH1 expression in the cells,
demonstrating that SAHA-induced resistance did not correlate
with loss of apoptosis.
SAHA-induced resistance and MDR1 expression. The
recently reported resistance to FK228 has been attributed to
the inducible and reversible expression of MDR1 (18,19). In
contrast, our observations (Fig. 5) showed that MDR1 was
not expressed in any of the cell lines or the respective SAHA-
induced sublines (untreated or treated with 15 μM SAHA for
14 h), demonstrating that SAHA-induced resistance was not
associated with induction of MDR1. Expression of MDR1
was also not detected in the VPA-induced sublines.
SAHA-induced resistance and HDAC1 and HDAC3 expression.
HDAC inhibitors cause hyperacetylation of histones and it was
thus determined whether the SAHA-induced, SAHA-resistant
sublines displayed hypoacetylation of the histones H2B, H3,
and H4 (relative to the non-induced cell lines). The immunoblot
results are shown (Fig. 6A). SAHA produced acetylation of
H3 and H4 in both non-induced cell lines (i.e. MLH1-proficient
and MLH1-deficient) as well as in the respective SAHA-
induced sublines, demonstrating that SAHA exerts its effect
in a target-specific manner. For the MLH1-proficient setting,
SAHA produced a higher acetylation of H3 and H4 in the
SAHA-induced, resistant subline (HCT116ch3/SAHA) than
in the non-induced cell line (HCT116ch3), indicating that
SAHA-induced resistance in MLH1-expressing cells was not
accompanied by hypoacetylation. This was different for the
MLH1-deficient setting. First, the level of acetylated H4 in
the SAHA-induced subline (HCT116ch2/SAHA) was similar
to that in the non-induced cell line (HCT116ch2). Second,
the level of acetylated H3 in the SAHA-induced subline
was lower than in the respective non-induced cell line. This
demonstrated that SAHA-induced resistance was accompanied
by hypoacetylation of only H3 and only in MLH1-deficient
cells. In addition, detection of acetylated histone H2B was
poor.
It was reasoned that SAHA-induced resistance could be
due to increased levels of HDACs present in the respective
sublines. This was not the case, as the SAHA-induced sublines
expressed levels of HDAC1, -3, -6, and -7 that were similar
to those expressed in the respective non-induced cell lines
(Fig. 6B). Expression of HDAC4 and HDAC5 was not
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Figure 4. (A) Induction of p21 and p27 by SAHA in untreated control
samples (no SAHA) and in samples captured 7 or 14 h after treatment with 5
or 15 μM SAHA. Actin is the sample loading control. Representative of two
independent experiments. (B) Induction of apoptosis (DNA fragmentation)
presented as the percentage of TUNEL-positive (apoptotic) cells as a function
of treatment with 15 μM SAHA (captured 24 h post treatment). Mean ± SD
of 3 independent data sets.
Figure 5. Expression of MDR1 as a function of a 14-h treatment with 15 μM
SAHA in the non-induced cell lines and the respective SAHA- or VPA-
induced sublines. A control lysate (sc-2284; Santa Cruz Biotechnology Inc.)
was used as a positive control for MDR1 (Co).
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detected. In addition, SAHA produced increases in the levels
of HDAC1 and HDAC3 in all the cell lines and the respective
sublines relative to untreated samples (Fig. 6C) and to a
comparable extent (Fig. 6D). This demonstrated that resistance
to SAHA was not accompanied by elevated expression of
HDAC1 and HDAC3 in these sublines.
Discussion
We observed the following: i) that HDAC inhibitors SAHA
and VPA induced HDAC inhibitor (cross-) resistance which
was not associated with cross-resistance to some none-HDAC
inhibitor-type anticancer agents; ii) that this type of HDAC
inhibitor-induced resistance was stable, MDR1-independent,
and not associated with elevated expression of HDAC1 and
HDAC3; iii) that the SAHA-induced resistance correlated
with defective activation of the G2/M checkpoint but not with
loss of p21 and p27 induction and apoptosis; and iv) that
MLH1 was irrelevant for the cytotoxic effect of SAHA and
VPA. We may conclude that a novel mechanism of induced
drug resistance, which is different to that observed with
FK228, underlies the herein described resistance induced by
these HDAC inhibitors.
The antineoplastic activity of HDAC inhibitors is an
unquestionable property of these compounds. However, our
observations with SAHA and VPA, together with those
reported for FK228 (18,19), may shed some light on another
less well-described aspect of HDAC inhibitors, namely their
potential to induce resistance in tumor cells. In general terms,
resistance induction may mean that existing cells are altered
by HDAC inhibitor exposure in that they acquire new features
in an irreversible fashion that renders them resistant (clonal
growth in the presence of an HDAC inhibitor) or it might
mean selection of those cells that are a priori more resistant
to cell killing by HDAC inhibitors. The former principle was
the basis of our experimental design, although a possible
contribution of the latter cannot be ruled out. Despite some
shared findings, our observations differ from those reported for
FK228 in several ways, indicating that different mechanisms
may underlie these resistance phenomena.
First, the SAHA- and VPA-induced resistance phenotype
is likely to be stable, as it was maintained for at least 6 months
(maximum period of observation) even in the absence of the
drugs in the culture medium, and unlikely to be due to differ-
ential growth rates of the HDAC inhibitor-induced sublines.
In contrast, FK228-induced resistance required the presence
of FK228 and correlated with slower growth rates (19).
Second, our results demonstrate that the SAHA- and VPA-
induced resistance is not dependent on the MDR1 transporter.
This is consistent with the findings that SAHA is not substrate
for MDR1 (9,18) and also explains why we did not observe
cross-resistance to ‘classic’ anticancer agents such as cisplatin
and docetaxel which are substrates for MDR1 (20). This is
opposed to the FK228-induced resistance that correlated with
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Figure 6. (A) Acetylation of histones H2B, H3, and H4. (B) Expression of HDACs in the non-induced cell lines and the SAHA-induced sublines. (C)
Expression of HDACs as a function of treatment with 15 μM SAHA in the non-induced cell lines and the respective SAHA-induced sublines captured 14 h
post treatment. (D) Quantitative presentation of the changes in HDAC1 and HDAC3 expression (relative to untreated controls and normalized against ß-actin
loading control).
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reversible MDR1 induction and cross-resistance to doxorubicin
and etoposide but not to SAHA and TSA (18,19). We also
found cross-resistance among members of structurally different
classes of HDAC inhibitors (e.g. the hydroxamic acid-like
SAHA versus the carboxylate-like VPA). It therefore seems
that mechanisms of resistance induction other than those
mediated by MDR1 are involved, and this may also explain
the rather low magnitude of resistance (2-fold) for SAHA
and VPA, as compared to the high degree of resistance (up to
1,700-fold) reported for FK228 (18). The finding that MDR1
is not involved in SAHA- and VPA-induced resistance suggests
that, despite their potential to induce modest resistance, these
HDAC inhibitors can be used in combination with other
antitumoral agents that are substrates for MDR1. In addition,
it remains to be seen whether this low-level resistance is
sufficient to accumulate a stably resistant subpopulation of
tumor cells and therefore to impair tumor treatment in in vivo
models, although this has been shown for the 2-fold cisplatin
resistance in MMR-deficient cells (27).
Candidate mechanisms of resistance may include differ-
ential induction of cell cycle checkpoints and apoptosis,
overexpression of HDACs, loss of HDAC expression due to
mutations, or even ‘off-target’ (i.e. HDAC-independent)
effects. Our particular interest was directed towards SAHA,
as it is considered one of the most potent and promising
HDAC inhibitors and is the first of its class to be granted
market approval. Our observations indeed demonstrated that
SAHA-induced resistance was accompanied by loss of the
G2/M checkpoint, meaning that this defective checkpoint may
provide these cells with a growth advantage over the SAHA-
sensitive cells. The involvement of HDAC inhibitors in G2/M
checkpoint control has been shown previously (26,28-30).
Other studies have shown that HDAC inhibitors regulate the
G1/S checkpoint, and this is via induction of p21, an HDAC
inhibitor-inducible endogenous cell cycle inhibitor (24,31).
Our observations indicate that neither the loss of the G1/S
checkpoint nor the failure to induce p21 accounted for SAHA-
induced resistance. In addition, loss of the G2/M checkpoint
was not accompanied by reduced induction of p27, a protein
also involved in regulation of HDAC inhibitor-mediated check-
point control (26,32) or by altered p53 expression. Furthermore,
SAHA-imposed apoptosis (8) was observed in the non-induced
(sensitive) cell lines as well as in the SAHA-induced (resistant)
sublines, indicating the SAHA resistance in these cells did not
correlate with loss of apoptosis.
It was reasoned that resistance to SAHA was due to an
increased expression of its specific targets. Consistent with a
previous study reporting HDAC inhibitor-imposed increases
in HDAC levels (33), SAHA-imposed increases in HDAC1
and HDAC3 expression were found, but these increases were
not more pronounced in the resistant sublines, suggesting that
resistance may not be caused by increased expression of
HDACs. Likewise, the acetylation status of histones H3 and
H4 was not generally lower in the resistant sublines, meaning
that SAHA specifically affected its targets and that resistance
may not be explained by the failure of SAHA to inhibit HDAC
activity.
It has been suggested that HDAC inhibitors may induce
abnormal DNA structures that can be recognized by DNA
repair proteins (16,17). Recently, HDAC inhibitor resistance
associated with loss of HDAC2 protein due to a truncating
mutation in the HDAC2 gene was reported in MLH1-deficient,
microsatellite-instable tumor cells (34). Therefore, we have
addressed the issue of whether the lack of MLH1 expression
reduces the cytotoxic effect of HDAC inhibitors, and our
results showed that this was not the case. We also questioned
whether the absence of MLH1 is a determinant for resistance
induction. Our observations showed that this was not the case
with SAHA and VPA. In addition, the presence of the extra
chromosomes within the cells used in this study is unlikely to
be critical for resistance induction by these HDAC inhibitors,
as we observed SAHA-induced resistance also for the parental
HCT116 cell line.
Although inconclusive, our data suggest a novel mechanism
of HDAC inhibitor-induced resistance that is not due to MDR1
expression, elevated expression of HDAC1 and HDAC3,
and reduced apoptosis. It is unclear whether SAHA-induced
resistance is a cell line- or tissue-specific phenomenon (it
was not seen with HeLa cells), and therefore it may thus not
be generalizable. In addition, the molecular bases of the
underlying mechanisms of this possibly novel type of HDAC
inhibitor induced resistance are still unknown and more
detailed studies are required to identify them. These include
microarray studies, the use of a larger set of cell lines, and
the consideration of other cellular drug detoxification systems.
The possibility should also be considered that this low-fold
resistance may be ascribed to subtle, chronic treatment-induced
differences in gene expression profiles that may be hard to
identify experimentally rather than being clearly ascribed to a
few single factors. 
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 6. Conclusion and perspective 
If drug resistance could be overcome, the impact on survival would with no doubt be highly 
significant. A large variety of different strategies aimed at overcoming drug resistance 
associated with tumor cells have been developed in the passed years. These include 
pharmacologic, genetic, or viral restoration of their ability to properly respond to anticancer 
therapies. Some strategies have even advanced into clinical applications. The advances in DNA 
microarray and proteomic technology, the researchers’ ability to characterize the signaling 
pathways involved in regulating tumor cell response to chemotherapy more completely than 
ever before, and the ongoing development of new targeted therapies will open up new 
opportunities to combat drug resistance. The ability to predict response to chemotherapy and to 
modulate this response with targeted therapies will permit selection of the best treatment for 
individual patients. 
 The prevention of drug resistance acquisition, the overcoming of intrinsic drug resistance, 
and the understanding of the underlying mechanisms of drug resistance (development) are of 
continuing interest in our research laboratory. Two of the key questions are: 
 
6.1. What is the molecular basis of the acquired resistance by HDAC inhibitors? 
We and others have shown that HDAC inhibitors can cause drug resistance development in 
tumor cells. However, the mechanisms underlying the above described and putatively novel 
type of acquired resistance by the HDAC inhibitor SAHA is still not understood at this point. 
Ongoing studies in our laboratory are thus aimed at uncovering the molecular basis of this type 
of acquired resistance. The data accumulated so far indicate that SAHA-induced resistance in 
HCT116 colorectal adenocarcinoma cells correlates with histone hypoacetylation. This, together 
with the observation that multidrug-resistance transporters are not affected (see 
PUBLICATION III; 18), suggests that SAHA may not do its job, i.e. may not inhibit HDAC 
activity, and thus does not result in acetylation of the histones in the SAHA-resistant cells. One 
of the questions is what is the reason why SAHA does not produce accumulation of acetylated 
histones in the resistant cells. Several possibilities are plausible and are summarized in a model 
chart (Figure 1). The failure of histone acetylation (hypoacetylation) may arise (i) from reduced 
uptake of SAHA, (ii) from increased sequestration/detoxification of SAHA, (iii) from reduced 
transport of SAHA into the nucleus (its compartment of action), or (iv) from decreased activity 
of histone acetyltransferases. In addition, resistance could also arise from the dysregulation of 
SAHA-mediated signaling pathways that favor survival and counteract cell death processes. 
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Figure 1: Simplified model showing the various histone and non-histone targets that are affected by 
histone deacetylase inhibitors (blue). SAHA enters cells either via passive diffusion or via active inward 
transport. Inside the cells SAHA binds to its substrates, i.e. HDACs, and blocks the catalytic site of the 
HDACs, resulting in accumulation of acetylated histones, in the decondensening of the chromatin 
(allowing for gene transcription), and in the accumulation of acetylated proteins (histone level). SAHA is 
proposed to also modulate mediators of signal transduction pathways (“off-target” level). The net effect 
of all this networking is the promotion of cellular responses that lead to cell death and growth inhibition 
and the abrogation of those that are survival-prone and promote growth. 
Also shown are the possible targets and mediators of (acquired) resistance to SAHA (red). Resistance to 
SAHA associated with histone hypoacetylation may be due 1) to reduced influx or 2) to increased efflux 
of SAHA (both processes reduce the intracellular concentration of SAHA); 3) to reduced transport of 
SAHA from the cytoplasm into the nucleus; 4) to the loss acetyltransferases HATs (prevents gene 
transcription); or 5) to mutations in HDAC genes (may prevent binding of SAHA). 6) It is also possible 
that resistance is due to dysregulation of signaling pathways responsive to HDAC inhibitors (shifts 
balance from cytodestructive towards cytoprotective properties). 
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It is also not clear why the expression of cell cycle regulation-associated proteins is 
apparently similar in SAHA-resistant cells and in SAHA-sensitive cells, suggesting that the loss 
of the G2/M checkpoint in the SAHA-resistant cells is not reflected by changes in the 
expression pattern of these proteins. Pilot data also indicate that acquired resistance to TSA 
seems to depend on the absence of MLH1 protein, suggesting that MLH1 protects via yet 
unknown mechanisms from resistance acquisition by TSA. Another open issue is whether 
SAHA-mediated resistance acquisition is a tumor cell line- and/or a tumor type-specific 
phenomenon. 
These issues are currently under investigation, which also includes microarray technology 
in order to identify genes or groups of genes that are differentially regulated and expressed in 
the sensitive and in the resistant cells. However, we cannot exclude at this point whether a 
multifactorial alteration of different cell regulating pathways that probably arises due to the 
epigenetic targeting of the HDAC inhibitors rather than one well understood single pathway 
may underlie SAHA resistance.  
 
 
6.2. Cytochrome c as therapeutic tool to overcome drug resistance? 
An intriguing approach pursued in our laboratory is aimed at delivering cytochrome c (from 
outside by a suitable carrier) directly into the cytoplasm where it associates with the 
apoptosome and eventually induces apoptosis. Cytochrome c is a protein with a highly 
conserved primary structure across different species localized in the mitochondrial 
intermembrane space. Normally it transfers electrons between complexes III and IV as part of 
the respiratory chain. Cytochrome c is also a critical protein in the intrinsic apoptotic pathway, 
inducing apoptosis when it is accumulated in the cytosol in response to pro-apoptotic stimuli. 
Cytosolic cytochrome c, together with APAF-1 and procpase-9, forms the apoptosome, which 
then activates the effector caspases-3 and -7 (80,81). Earlier studies have shown that direct 
microinjection of cytochrome c into the cytoplasm of a cell or delivery by electroporation 
activates apoptosis (82,83). As these applications are hardly suitable for treatments in patients, 
we use cytochrome c encapsulated in liposomes. This bio-compatible cytochrome c (drug) 
delivery would also have an additional benefit: the reduction of the severe adverse side effects 
often seen with chemotherapies using "classic" apoptosis-inducing agents. Preliminary data 
from our laboratory are promising, as they indicate that cytochrome c-encapsulated liposome 
but not liposomes without encapsulated cytochrome c induce apoptosis in HeLa cervical tumor 
cells. 
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 This approach may also be useful for drug resistance reversal (Figure 2). We propose that 
cytochrome c delivered this way would induce apoptosis even in tumor cells resistant to 
apoptosis-inducing anticancer agents. This is because cytochrome c, coming into action 
downstream of apoptosis-inducing signaling cascades and independently of additional pro-
apoptotic stimuli, would overcome the lack of these apoptosis-signaling processes. Such 
processes are frequently absent in drug-resistant tumor cells, for instance due to MDR 
overexpression or due to the defective apoptosis initiation machinery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Tentative chart of restoration of drug sensitivity by delivering exogenous cytochrome c (cyto 
c) into the cytoplasm by a liposomal carrier. (Right insert) Tumor cell that has become drug-resistant due 
to overexpression of multidrug resistance transporters (e.g. MDR), drug-inactivating proteins (e.g 
glutathione/glutathione-transferase), or anti-apoptotic factors (e.g. Bcl-2), DNA damage tolerance (e.g. 
MMR), or dysregulated stress-responsive pathways (e.g. p53) and therefore displays insufficient 
(endogenous) apoptosis signaling. Consequently, cyto c is not released from the mitochondria, the 
apoptosome is not formed, and caspase-mediated apoptosis is not initiated (A). 
(Left) Liposome-encapsulated exogenous cyto c delivered to the tumor cell by endocytosis (1), forming 
an endosome-encapsulated/cyto c-liposome “hybrid” (2). Cyto c is released from the endosome/liposome 
into the cytoplasm (3), thereby bypassing the absence of mitochondrial cyto c release due to lack of or 
insufficient (endogenous) apoptosis signaling. This exogenously delivered, cytoplasmic cyto c is 
incorporated together with APAF-1 and pro-caspase-9 into the apoptosome (4). Subsequent activation of 
pro-caspase-9 cleaves (activates) the pro-caspases-3 and/or -7 which, in turn, cleave PARP-1 and other 
substrates, finally leading to the destruction of the tumor cell by apoptosis (5). 
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